Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4788 companies, A–Z).
Solidion Technology reported third-quarter 2026 results, with revenue of $41,638 compared with $9,350 a year earlier and net income of approximately $244,000 compared with a net loss of $4.1 million in the prior-year period. Cash and cash equivalents were $26.2 million at September 30, 2026, and total liabilities fell about 40% from year-end 2025, which the company says supports its capacity to pursue acquisitions.
Q3 2026 revenue was $41,638, up from $9,350 in Q3 2025; basic EPS was $0.02 versus a loss of $1.33 per share.
Net income was approximately $244,000 for the quarter, compared with a net loss of $4.1 million in the prior-year period.
Cash and cash equivalents were $26.2 million at September 30, 2026, down from $27.7 million at June 30, 2026.
On September 13, 2026, the Board authorized repurchases of up to $1.0 million of common stock.
Mueller Water Products furnished an updated investor presentation dated November 11, 2026, which reports results for the fiscal year ended September 30, 2026. Net sales were $1,475.0 million, up from $1,429.7 million in FY2025, and net income rose to $221.9 million from $191.7 million. Shareholders get a fuller view of profit and cash flow, which the company says reflects a third consecutive year of record results.
FY2026 net sales of $1,475.0 million, compared with $1,429.7 million in FY2025.
Net income of $221.9 million, or $1.41 per diluted share, compared with $191.7 million, or $1.22 per share.
Adjusted EBITDA of $372.2 million, compared with $326.2 million; adjusted EPS of $1.57, compared with $1.31.
Free cash flow of $207.3 million, compared with $172.0 million; strategic reorganization and other charges were $27.8 million.
EquipmentShare reported third-quarter 2026 results for the period ended September 30, 2026, with total revenue up 55% year over year to $1,468 million and net income of $20 million, compared with $6 million a year earlier. Adjusted Core EBITDA rose 40% to $594 million, and management said it is confident in its full-year 2026 outlook and sees an opportunity to outperform it. For shareholders, both headline revenue and profit grew, though GAAP net income remains small relative to revenue and interest expense was $88 million in the quarter.
Total revenue rose 55% to $1,468 million from $945 million; Rental Segment revenue rose 49% to $1,113 million.
Net income was $20 million versus $6 million; Adjusted Net Income, which excludes $26 million of IPO Founders Awards stock compensation, was $46 million.
Adjusted Core EBITDA increased 40% to $594 million; net leverage fell to 3.4x from 3.7x a year earlier.
Current 2026 guidance ranges include total revenue of $5,808 million to $6,045 million and Adjusted Core EBITDA of $2,136 million to $2,224 million.
Tidewater reported third-quarter 2026 revenue of $360.4 million, up from $341.1 million a year earlier, and net income attributable to the company of $17.5 million, or $0.35 per diluted share, compared with a loss of $0.8 million a year earlier. The company also initiated 2027 revenue guidance of $1.70 to $1.75 billion and updated its 2026 revenue guidance to $1.43 to $1.44 billion, while closing a $500 million all-cash acquisition of Wilson Sons Ultratug Offshore.
Q3 2026 revenue of $360.4 million, up 5.3% from the second quarter of 2026
Q3 2026 net income of $17.5 million ($0.35 per diluted share), versus a $0.8 million loss a year earlier
Nine-month 2026 net income of $45.3 million, down from $114.8 million in the first nine months of 2025
2027 revenue guidance of $1.70 to $1.75 billion; 2026 revenue guidance updated to $1.43 to $1.44 billion
GMR Solutions reported third quarter 2026 net revenue of $1,595.6 million, up 5.9%, and net income of $135.6 million, up 81.7%, and updated its full year 2026 guidance. Adjusted EBITDA rose 4.2% to $356.6 million in the quarter, but nine-month Adjusted EBITDA grew only 0.4%, and the filing does not state the prior guidance, so the direction of the update cannot be judged from it.
Q3 2026 net revenue $1,595.6 million, up 5.9% from $1,506.9 million; net income $135.6 million, up from $74.6 million
Q3 2026 Adjusted EBITDA $356.6 million, up 4.2%; nine-month Adjusted EBITDA $946.1 million, up 0.4%
Updated full year 2026 guidance: net revenue $5,900 million to $6,050 million; Adjusted EBITDA $1,135 million to $1,195 million
Liquidity of approximately $999.3 million at September 30, 2026, including $298.0 million of cash; $200.0 million of term loan repaid in a September 17, 2026 repricing
Elmet Group reported third-quarter 2026 results for the period ended October 2, 2026, with revenue up 55.6% to $79.6 million and net income of $8.3 million, or $0.24 per diluted share, compared with $1.6 million, or $0.08, a year earlier. Gross margin rose to 31.3% and open order backlog reached a company record $347.4 million, though nine-month net income fell to $3.5 million from $4.0 million and the release gives no new guidance.
Q3 revenue was $79.6 million versus $51.1 million a year earlier; gross profit margin was 31.3% versus 21.7%.
Adjusted EBITDA was $17.0 million, or 21.3% of revenue, versus $7.4 million, or 14.5%, in Q3 2025.
Q3 net income was $8.3 million, or $0.24 per diluted share, versus $0.08 per diluted share a year earlier.
Nine-month net income was $3.5 million, or $0.10 per diluted share, versus $4.0 million, or $0.20, for the nine months ended September 30, 2025.
AST SpaceMobile reported third quarter 2026 revenue of $42.3 million, up from $14.7 million a year earlier, and a net loss attributable to common stockholders of $132.4 million, or $0.44 per share, compared with $122.9 million, or $0.45 per share, in the third quarter of 2025. The company said it remains on target for its revenue guidance of $150.0 million to $200.0 million and cited about $1.0 billion in non-dilutive Japanese government funding for satellite manufacturing and launch.
Q3 2026 total revenue was $42.3 million versus $14.7 million in Q3 2025; nine-month revenue was $88.6 million versus $16.6 million
Net loss attributable to common stockholders was $132.4 million, or $0.44 per share, versus $122.9 million, or $0.45 per share, a year earlier
Company remains on target for 2026 revenue guidance of $150.0 million to $200.0 million
Cash, cash equivalents and restricted cash were approximately $3.2 billion as of September 30, 2026
Bally's preliminary third-quarter 2026 consolidated revenue rose 21.7% year over year to $807.6 million, with growth led by Bally's Intralot B2C and North America Interactive. The company said it expects to file a Rule 12b-25 extension and its Form 10-Q within the extension period, and the figures remain subject to its close process. The results are preliminary and unaudited, so shareholders should watch for the final 10-Q.
Preliminary Q3 2026 revenue was $807.6 million, up from $663.7 million a year earlier
Bally's Intralot B2C revenue rose 22.8% to $257.5 million, while its Adjusted EBITDAR fell to $77.0 million from $86.4 million
The company expects to file a Rule 12b-25 extension and its 10-Q within the extension period
On October 1, 2026, Bally's closed Bronx project financing, receiving $400 million with $160 million more available for future draws
Mesa Laboratories reported fiscal second-quarter revenue of $62.3 million, up 2.6%, and net income of $4.3 million, up 75.3%, or $0.75 per diluted share versus $0.45 a year earlier. The company also issued its first fiscal 2027 guidance, calling for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, and authorized a share repurchase of up to $40 million.
Q2 revenue $62.3 million, up 2.6%; adjusted EBITDA $17.3 million, up 21.1%, or 27.8% of revenue
Fiscal 2027 guidance (year ending March 31, 2027): revenue $250 million to $255 million; adjusted EBITDA $66 million to $68 million
Board terminated its 2005 buyback program on November 4, 2026 and authorized up to $40 million in repurchases through December 31, 2028
Savings Plan announced October 13, 2026 expects total pre-tax restructuring charges of $2.6 million to $3.4 million, mainly in the second half of fiscal 2027
Babcock & Wilcox reported third quarter 2026 revenue of $290.8 million, up from $139.2 million a year earlier, and net income of $93.9 million, up from $35.1 million. Net income was lifted by an $85.1 million change in the fair value of customer warrants, and adjusted net income was $4.8 million. The company reiterated its 2026 Adjusted EBITDA target of $80.0 million to $105.0 million and issued a 2027 Adjusted EBITDA target of $125 million to $140 million.
Q3 2026 revenue of $290.8 million vs. $139.2 million in Q3 2025; Adjusted EBITDA of $17.7 million vs. $9.4 million
Net income of $93.9 million includes an $85.1 million change in fair value of customer warrants; adjusted net income was $4.8 million
Basic EPS of $0.61 vs. $0.30 in Q3 2025; Q3 bookings of $228 million and backlog of $2.5 billion
2026 Adjusted EBITDA target of $80.0 million to $105.0 million reiterated; 2027 target of $125 million to $140 million issued
P3 Health Partners reported third quarter 2026 revenue of $396 million, up 15% from a year earlier, and net income of $30.8 million versus a net loss of $69.5 million in the prior-year quarter. The company raised the low end of its full-year 2026 Adjusted EBITDA guidance to $90 million, moving the midpoint to $100 million, though the quarter also benefited from payer settlements and prior-year development.
Q3 2026 total revenue was $396 million, up 15% from $345 million a year earlier.
Q3 2026 Adjusted EBITDA was $20.9 million, compared with a loss of $45.9 million in Q3 2025.
Full-year 2026 Adjusted EBITDA guidance is now $90 million to $110 million, up from a lower low end.
Q3 medical margin of $43.9 million included favorable payer settlements; excluding these items it was $35.0 million.
AbCellera reported third-quarter 2026 results, with total revenue of $10.6 million versus $9.0 million a year earlier and a net loss of $40.8 million, or $(0.13) per share, down from $57.1 million, or $(0.19) per share. The company said it had over $890 million in total available liquidity as of September 30, 2026, including a $200 million share offering that closed August 14, 2026 at $9.75 per share.
Total revenue of $10.6 million in Q3 2026, compared with $9.0 million in Q3 2025
Net loss of $40.8 million, or $(0.13) per share, compared with $57.1 million, or $(0.19) per share, in Q3 2025
R&D expenses of $43.5 million, down from $55.0 million; SG&A expenses of $13.6 million, down from $25.0 million
Positive top-line Phase 2 data for ABCL635 announced in Q3; Phase 1 top-line data for ABCL575 announced after quarter end
FutureFuel reported third-quarter 2026 results on November 9, 2026. Revenue rose 361% to $104.7 million, driven by biofuel volume and pricing, and the net loss narrowed to $8.4 million from $9.2 million, although the company still posted a gross loss and a shrinking cash balance. The company expects positive Adjusted EBITDA in the fourth quarter and for full-year 2026, after a nine-month Adjusted EBITDA loss of $6.9 million.
Q3 2026 total revenue was $104.7 million, up from $22.7 million in Q3 2025; biofuel revenue was $87.8 million.
Net loss was $8.4 million, or $0.19 per diluted share, compared with a $9.2 million net loss in Q3 2025.
Q3 Adjusted EBITDA was a loss of $4.9 million; the company expects fourth-quarter Adjusted EBITDA of approximately $7 million.
Cash and cash equivalents were $21.3 million at September 30, 2026, down from $34.3 million at June 30, 2026.
Coherus Oncology reported third quarter 2026 net revenue from continuing operations of $14.3 million, up from $11.6 million a year earlier, and a narrower net loss from continuing operations of $38.9 million, or $(0.25) per share, versus $44.5 million, or $(0.38) per share. The company also announced a strategic prioritization plan that focuses tagmokitug development on esophageal cancer and reduces headcount by about 30%, with the CFO saying these benefits will be realized over the next two quarters.
Q3 2026 net revenue from continuing operations was $14.3 million, versus $11.6 million in Q3 2025; LOQTORZI revenue was $14.0 million, up 25% from $11.2 million.
Q3 2026 GAAP net loss from continuing operations was $38.9 million, or $(0.25) per share, versus $44.5 million, or $(0.38) per share, in Q3 2025.
Right-sizing reduces headcount by about 30% and is expected to lower core cash burn by $6 million to $7 million per quarter.
Cash, cash equivalents and marketable securities were $83.6 million at September 30, 2026, versus $172.1 million at December 31, 2025.
Lincoln Educational Services reported third-quarter 2026 revenue of $159.2 million, up 12.6% from $141.4 million, with net income of $4.7 million, up from $3.8 million. The company raised its full-year 2026 revenue guidance to $600.0 million to $605.0 million while reiterating its adjusted EBITDA guidance of $76.0 million to $80.0 million.
Q3 2026 revenue of $159.2 million, up from $141.4 million; net income of $4.7 million, up from $3.8 million
Diluted EPS of $0.15 versus $0.12; adjusted EBITDA of $17.4 million, up 30.8%
2026 revenue guidance raised to $600.0 million to $605.0 million; student start growth guidance narrowed to 10% to 12%
Board raised the share repurchase authorization by $30 million to $70 million total, with more than $37 million remaining
ImageneBio reported third quarter 2026 results, with a net loss of $15.6 million, or $0.91 per share, down from $24.8 million, or $2.91 per share, a year earlier. The company had no revenue in either period, and lower research and development and general and administrative expenses drove the smaller loss. It ended the quarter with $126.6 million in cash, cash equivalents and marketable securities, which it expects will fund planned operations into the first quarter of 2028.
Net loss was $15.6 million for the three months ended September 30, 2026, compared with $24.8 million a year earlier.
Net loss per share was $0.91, compared with $2.91 a year earlier.
R&D expenses fell to $11.3 million from $15.2 million, and G&A expenses fell to $6.0 million from $11.0 million.
Cash position was $126.6 million as of September 30, 2026, with funding expected into the first quarter of 2028.
Atea Pharmaceuticals reported a third-quarter 2026 net loss of $32.2 million, or $0.40 per share, down from $42.0 million, or $0.53 per share, a year earlier, as research and development spending fell. The company also secured a credit facility with Hercules Capital of up to $200 million, of which $65 million was drawn on November 6, 2026, and said current resources fund operations into mid-2028.
Net loss was $32.2 million, or $0.40 per share, for the three months ended September 30, 2026, versus $42.0 million, or $0.53 per share, a year earlier.
Cash, cash equivalents and marketable securities were $191.2 million at September 30, 2026, versus $301.8 million at December 31, 2025.
Hercules Capital facility of up to $200 million; $65 million drawn at closing on November 6, 2026, with up to $135 million more subject to milestones.
Phase 3 C-BEYOND trial met its primary endpoint: 93.91% SVR for BEM/RZR versus 94.75% for Epclusa; C-FORWARD topline results expected in early 2027.
AMCON Distributing reported results for the fiscal year ended September 30, 2026, with diluted earnings per share of $2.52 compared with $0.62 in the prior year. Sales rose to $3.12 billion from $2.82 billion, and the retail health food segment posted an operating loss while the wholesale segment reported operating income.
Net income available to common shareholders was $2.4 million, compared with $0.6 million in fiscal 2025.
Sales were $3.12 billion, compared with $2.82 billion in fiscal 2025.
Wholesale distribution segment operating income was $25.5 million; retail health food segment operating loss was $0.6 million.
Shareholders' equity was $117.0 million at September 30, 2026.
Verde Clean Fuels reported third-quarter 2026 results, with a net loss of $2.0 million, or $(0.04) per Class A share, compared with a net loss of $2.3 million, or $(0.06) per share, a year earlier. The company attributed the smaller loss mainly to cost savings, partly offset by higher share-based compensation, and reported $52.6 million in cash and no debt as of September 30, 2026.
Q3 2026 net loss of $2.0 million vs. $2.3 million in Q3 2025; diluted loss per Class A share of $(0.04) vs. $(0.06)
Nine-month 2026 net loss of $6.3 million vs. $7.6 million in the same period of 2025; loss per share of $(0.14) vs. $(0.21)
Cash and cash equivalents of $52.6 million and no debt as of September 30, 2026
The company said it continues to evaluate strategic alternatives and opportunities to deploy its STG+ technology
AlTi Global reported third-quarter 2026 results in an investor presentation furnished under Item 2.02 and Item 7.01. Revenue edged up 1% year over year, operating expenses fell 25%, and the net loss from continuing operations narrowed sharply, which points to improved profitability for shareholders. The filing contains no guidance update.
Revenue was $58 million, up 1% from $57.2 million a year earlier, with management fees up 7% to $55 million
Total operating expenses fell 25% year over year to $64 million
Operating loss narrowed to $6 million from $28.5 million a year earlier; net loss from continuing operations was $11.4 million versus $87.0 million
Adjusted EBITDA was $6.2 million, up 1% year over year, with a 10.8% margin
EVI Industries reported results for the first fiscal quarter of 2027, ended September 30, 2026, with revenue up 4.3% to a record $112.9 million and net income up 108% to $3.8 million. Net debt rose to $76.7 million from $44.2 million at June 30, 2026, mainly from borrowings for the Sudsies acquisition, which matters to shareholders because it increases the company's leverage.
Revenue increased 4.3% to $112.9 million; gross profit rose 12% to $38.0 million
Operating income increased 75% to $6.2 million; net income increased 108% to $3.8 million
Diluted earnings per share were $0.24, compared with $0.11 a year earlier
Net debt was $76.7 million at September 30, 2026, compared with $44.2 million at June 30, 2026
Groupon reported third-quarter 2026 results for the period ended September 30, 2026, with global revenue up 2% and billings up 6% year over year. The loss from continuing operations narrowed to $0.8 million from $117.8 million a year earlier, while Adjusted EBITDA fell to $14.7 million from $17.5 million, and the company gave full-year 2026 revenue guidance of $500 million to $503 million.
Global revenue rose 2% and billings rose 6% year over year in Q3 2026; North America Local Revenue was flat.
Loss from continuing operations was $0.8 million, compared with $117.8 million in Q3 2025.
Adjusted EBITDA was $14.7 million, compared with $17.5 million a year earlier; free cash flow was negative $45.8 million.
For 2026, the company expects revenue of $500 million to $503 million and Adjusted EBITDA of $60 million to $65 million; management will host an investor update on December 8, 2026.
Life360 reported third-quarter 2026 total revenue of $174.1 million, up 40% from a year earlier, with net income of $22.5 million, up 130%, including a $17.5 million investment fair value gain. The company narrowed its full-year 2026 guidance for consolidated revenue to $665 million to $681 million and for Adjusted EBITDA to $132 million to $138 million, and reported $44.4 million in share repurchases to date.
Q3 2026 total revenue of $174.1 million, up 40% YoY; advertising revenue of $25.4 million, up 250% YoY
Net income of $22.5 million, up 130% YoY, including a $17.5 million net gain on fair value of investments
Adjusted EBITDA of $34.6 million, up 41% from $24.5 million in Q3 2025
FY26 consolidated revenue guidance of $665 million to $681 million, versus the prior $650 million to $685 million; Adjusted EBITDA guidance of $132 million to $138 million, narrowed from $130 million to $140 million
Clearway Energy reported third-quarter 2026 revenue of $522 million, up from $429 million a year earlier, and net income of $123 million, up from $60 million. The company reaffirmed its 2026 CAFD guidance of $430 million to $470 million and set a 2027 CAFD guidance range of $520 million to $590 million. Net income attributable to Clearway Energy, Inc. fell to $51 million from $232 million, so shareholder-level earnings were lower.
Q3 2026 revenue $522 million vs. $429 million in Q3 2025; Adjusted EBITDA $435 million vs. $385 million
Net income attributable to Clearway Energy, Inc. was $51 million ($0.42 per share) vs. $232 million ($1.97 per share) a year earlier
2026 CAFD guidance reaffirmed at $430 million to $470 million; 2027 CAFD guidance set at $520 million to $590 million
Board declared a quarterly dividend of $0.4824 per share payable December 15, 2026, to holders of record as of December 1, 2026
Greystone Housing Impact Investors LP reported third-quarter 2026 net income of $3.2 million, or $0.09 per BUC, compared with $851,000 in the same quarter of 2025, and total revenues of $21.95 million, up from $21.11 million. Cash Available for Distribution was $3.8 million, or $0.17 per BUC, versus $0.18 a year earlier, and the quarterly distribution was $0.14 per BUC, down from $0.30 in the prior-year quarter. The partnership is reducing its market-rate multifamily joint venture equity investments and redeploying capital into tax-exempt mortgage revenue bonds, and it said the pace of sales will affect near-term results.
Q3 2026 net income of $3.2 million, or $0.09 per BUC, versus $851,000, or $(0.01) per BUC, in Q3 2025
Total revenues of $21.95 million for Q3 2026, versus $21.11 million a year earlier
Quarterly distribution of $0.14 per BUC, paid October 30, 2026, versus $0.30 declared in Q3 2025
Five MRBs tied to a single borrower were behind on debt service as of September 30, 2026; payments were received on four of the five as of the filing date
Octave Specialty Group reported third quarter 2026 results, with total revenue up 28% to $85.3 million and a net loss from continuing operations attributable to shareholders of $13.8 million, compared with $31.7 million a year earlier. The company also said that after quarter end, Everspan agreed to sell its Providence Washington Insurance Company subsidiary, which it expects to simplify its operating structure and strengthen its capital base.
Total revenue rose 28% to $85.3 million from $66.6 million in the third quarter of 2025.
Net loss from continuing operations attributable to shareholders was $13.8 million, or $0.31 per diluted share, versus $31.7 million, or $0.65 per share, a year earlier.
Adjusted EBITDA to shareholders was $3.3 million, compared with a loss of $2.9 million in the prior-year period.
Management expects market softening to continue into 2027; the earnings call is scheduled for November 10, 2026, at 8:30am ET.
OraSure Technologies reported third-quarter 2026 results, with total net revenues up 14% year over year to $30.9 million and a GAAP net loss of $13.1 million, compared with $13.7 million a year earlier. The company guided fourth-quarter 2026 revenue to $30.0 million to $32.0 million and expects full-year 2026 growth of 4.7% at the midpoint of the range. For shareholders, the quarter shows higher sales and a smaller loss, but nine-month revenue rose only 1%.
Q3 2026 total net revenues were $30.9 million, up 14% from $27.1 million in Q3 2025.
GAAP gross margin was 45.2%, compared with 43.5% a year earlier; GAAP net loss was $13.1 million versus $13.7 million.
Q4 2026 revenue guidance is $30.0 million to $32.0 million; full-year 2026 growth is 4.7% at the midpoint.
Cash and cash equivalents were $148 million as of September 30, 2026, after $7.0 million of nine-month share repurchases.
Qualys reported third-quarter 2026 revenue of $188.0 million, up 11% from $169.9 million a year earlier, and GAAP diluted earnings of $1.62 per share versus $1.39. The company raised its full-year 2026 revenue guidance to $736.9 million-$738.9 million from $732.0 million-$738.0 million and its GAAP EPS guidance to $6.08-$6.15 from $5.76-$5.90, which points to a higher outlook for shareholders.
Q3 revenue $188.0 million, up 11% from $169.9 million; GAAP net income $57.2 million
GAAP diluted EPS $1.62 vs. $1.39; non-GAAP diluted EPS $2.12 vs. $1.86
Full-year 2026 revenue guidance raised to $736.9 million-$738.9 million; GAAP EPS guidance raised to $6.08-$6.15
Q4 2026 revenue guidance set at $191.0 million-$193.0 million, 9% to 10% growth
Lucid reported third quarter 2026 revenue of $350.3 million, up from $336.6 million a year earlier, and a net loss of $830.9 million, down from $978.4 million. Free cash flow consumption fell 30% sequentially to $1.04 billion, and a $1.75 billion increase to the PIF-backed DDTL facility, announced with the results, lifts pro forma liquidity to $3.75 billion. Lucid says this liquidity should fund operations into Q4 2027, through the Midsize production start.
Q3 2026 revenue was $350.3 million, up from $336.6 million in Q3 2025; net loss per share was $(2.74) versus $(3.31).
Free cash flow consumption declined 30% sequentially to $1.04 billion.
Total liquidity was $2.0 billion at quarter end, or $3.75 billion pro forma for the $1.75 billion DDTL increase.
Year-to-date cash flow improvement savings reached $0.8 billion against a full-year target of $1.4 billion.
PubMatic reported third-quarter 2026 revenue of $79.6 million, up 17% from a year earlier, and GAAP net income of $5.5 million, or $0.11 per diluted share, compared with a net loss of $6.5 million in the prior-year quarter. Its Board also authorized an additional $150 million for share repurchases and extended the program through December 31, 2028, bringing the total available to approximately $198 million.
Q3 2026 revenue was $79.6 million, up 17% year over year; adjusted EBITDA was $26.0 million, versus $11.2 million in Q3 2025.
GAAP net income was $5.5 million ($0.11 per diluted share), compared with a net loss of $6.5 million ($0.14 per share) in Q3 2025.
Q4 2026 revenue guidance is $91 million to $93 million, and full-year 2026 revenue guidance is $312 million to $314 million.
On November 9, 2026, the Board authorized $150 million of additional repurchases, with the program running through December 31, 2028.
Trump Media & Technology Group reported third-quarter 2026 revenue of $3.0 million, up from $1.0 million a year earlier, and net income of $409.7 million. Most of the profit came from non-cash gains on digital assets and equity securities, and Adjusted EBITDA was a $12.3 million loss, narrower than the $29.1 million loss in the third quarter of 2025.
Revenue rose 205% year over year, driven by $1.8 million of Media segment subscription growth from Truth API, which launched August 1, 2026, and Truth+, plus $0.2 million in Truth.Fi management fees.
Net income of $409.7 million included $496.1 million of net realized and unrealized gains on digital assets, pledged digital assets and equity securities.
Adjusted EBITDA was a $12.3 million loss in the third quarter of 2026, compared with a $29.1 million loss in the third quarter of 2025.
Legal fees fell to $2.4 million from $20.3 million, and cash used in operating activities for the nine months ended September 30, 2026 was $28.4 million.
Zymeworks reported third quarter 2026 net income of $173.7 million, compared with a net loss of $19.6 million a year earlier, driven mainly by a $250 million milestone from Jazz Pharmaceuticals after the U.S. approval of Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma. The company raised its 2026 total revenue guidance to $337 million to $351 million from $278 million to $292 million. Higher selling, general and administrative costs tied to the Theravance Biopharma acquisition partly offset the gain.
Q3 2026 total revenue was $256.5 million, compared with $27.6 million in Q3 2025.
Q3 2026 diluted earnings per share were $2.28, compared with a loss of $0.26 per share in Q3 2025.
2026 adjusted EBITDA guidance was raised to $176 million to $190 million from $114 million to $128 million.
SG&A expenses rose to $42.7 million from $14.1 million, mainly due to Theravance Biopharma acquisition costs, which closed September 23, 2026.
Onto Innovation reported fiscal third-quarter 2026 revenue of $409.7 million, up 87.8% from a year earlier, with GAAP net income of $46.8 million, or $0.95 diluted EPS, versus $0.57 a year earlier. The company also guided fourth-quarter 2026 revenue to $430 million to $450 million and non-GAAP diluted EPS to $2.59 to $2.79, while a $40.8 million unrealized loss on its Rigaku investment weighed on GAAP results.
Q3 revenue of $409.7 million vs. $218.2 million in Q3 2025; non-GAAP diluted EPS of $2.44 vs. $0.92
GAAP net income of $46.8 million includes a $40.8 million unrealized loss on the Rigaku investment
Q4 2026 guidance: revenue of $430 million to $450 million; GAAP diluted EPS of $1.95 to $2.07
Cash, equivalents and marketable securities of $1.25 billion at September 30, 2026; backlog above $1.3 billion
Plug Power reported third-quarter 2026 revenue of about $201 million, up about 13% from a year earlier, with a narrower gross loss and operating loss. GAAP net income was positive, but the company says it was mainly driven by non-cash mark-to-market gains, and the company reiterated its 2026 revenue growth guidance of 15% to 16% and its target of positive EBITDAS in Q4 2026.
Q3 2026 net revenue was $200.6 million, compared with $177.1 million in Q3 2025.
Gross loss narrowed to $5.4 million from $120.2 million; operating loss narrowed to $75.3 million from $348.8 million.
Net income attributable to Plug Power was $99.8 million, or $0.07 basic EPS, versus a loss of $0.31 per share, driven mainly by about $192 million in non-cash gains.
Net cash usage was about $28 million, down from about $61 million in Q2 2026; cash and cash equivalents excluding restricted cash were $134.1 million at September 30, 2026.
Hyperfine reported third quarter 2026 revenue of $6.0 million, up 73% from $3.4 million a year earlier, and a net loss of $6.0 million, or $0.06 per share, versus $11.0 million, or $0.14 per share, in the third quarter of 2025. The company reiterated its full-year 2026 guidance for revenue of $20 to $22 million and net cash burn of $26 to $28 million, so shareholders see improved results with no change to outlook, though the quarter's loss benefited from a $1.5 million warrant fair-value gain.
Q3 2026 revenue was a record $6.0 million, up 73% from $3.4 million; 14 commercial Swoop systems were sold versus 8 a year earlier.
Net loss was $6.0 million, or $0.06 per share, compared with $11.0 million, or $0.14 per share, in Q3 2025; the result includes a $1.5 million gain from warrant liabilities.
2026 guidance was reiterated: revenue of approximately $20 to $22 million and net cash burn of approximately $26 to $28 million.
Cash and cash equivalents were $37.9 million at September 30, 2026, with no financing proceeds in Q3; a new Form S-3 shelf of $150 million is expected to replace the one expiring in November 2026.
Kaltura reported third-quarter 2026 total revenue of $47.3 million, up 8% from a year earlier, and a net loss of $1.5 million, or $0.01 per diluted share, narrowed from $2.6 million in the prior-year quarter. The company raised its full-year 2026 guidance for subscription revenue, total revenue and adjusted EBITDA for the third time this year, which matters to shareholders because it signals stronger expected results, although Media & Telecom revenue declined 10%.
Total revenue was $47.3 million, up 8% from $43.9 million; subscription revenue was $45.9 million, up 9%.
Full-year 2026 total revenue guidance is now $185.0 million to $185.7 million, and adjusted EBITDA guidance is $19.5 million to $20.5 million.
Net loss was $1.5 million, or $0.01 per diluted share, compared with $2.6 million, or $0.02, in Q3 2025.
Media & Telecom revenue fell 10% year over year, while cash flow from operations was $7.6 million.
Sanmina reported unaudited fourth-quarter fiscal 2026 results for the quarter ended October 3, 2026, with revenue of $3.86 billion, GAAP diluted EPS of $2.14 versus $0.88 a year earlier, and gave fiscal 2027 revenue guidance of $17.5 billion to $19.5 billion. The company also disclosed Amendment No. 5 to its credit agreement, which adds $70 million of term A loans and extends key debt maturities to October 28, 2031.
Q4 revenue $3.86 billion vs $2.10 billion a year earlier; GAAP diluted EPS $2.14 vs $0.88; non-GAAP diluted EPS $4.43 vs $1.67
Q1 fiscal 2027 outlook: revenue $3.8 billion to $4.1 billion; non-GAAP diluted EPS $3.50 to $3.85
Fiscal 2027 outlook: revenue $17.5 billion to $19.5 billion; non-GAAP diluted EPS $15.50 to $17.50
Amendment No. 5 dated October 27, 2026 adds $70 million of term A-1 loans, returns the term loan A facility to $1.4 billion, and extends the $1.5 billion revolver to October 28, 2031
Digital Turbine reported fiscal second quarter 2027 revenue of $178.7 million, up 27% from $140.4 million a year earlier, and GAAP net income of $10.3 million, or $0.06 per diluted share, compared with a net loss of $21.4 million a year earlier. The company also gave fiscal 2027 guidance of $670 million to $690 million in revenue and $145 million to $155 million in non-GAAP adjusted EBITDA, and disclosed a $3.5 million revision to prior-period revenue share expense.
Q2 fiscal 2027 revenue was $178.7 million, up 27% from $140.4 million; non-GAAP adjusted EBITDA was $39.8 million, up 46%
GAAP net income was $10.3 million, or $0.06 per diluted share, versus a net loss of $21.4 million, or $(0.20) per share, a year earlier
Fiscal 2027 outlook: revenue of $670 million to $690 million and non-GAAP adjusted EBITDA of $145 million to $155 million
Prior-period revision understated revenue share expense by $3.5 million for the quarter ended June 30, 2026
Lantronix reported fiscal first-quarter 2027 results for the quarter ended September 30, 2026, with revenue of $32.4 million, up 8% from a year earlier, and a GAAP net loss of $463 thousand, down from $1.4 million. The company also gave second-quarter revenue guidance of $32.5 million to $34.5 million and reaffirmed its expectation for double-digit revenue growth in fiscal 2027.
Revenue was $32.4 million, up from $29.8 million in the same quarter a year earlier.
GAAP net loss was $463 thousand, or $0.01 per share, compared with a net loss of $1.4 million, or $0.04 per share, a year earlier.
Non-GAAP net income rose 50% to $2.2 million, or $0.05 per share.
Second-quarter fiscal 2027 revenue outlook is $32.5 million to $34.5 million; double-digit revenue growth for fiscal 2027 was reaffirmed.
Paysign reported third-quarter 2026 revenue of $30.80 million, up 42.6%, and GAAP net income of $6.74 million, or $0.11 per diluted share, versus $0.04 a year earlier. The company raised its full-year 2026 net income, diluted EPS and Adjusted EBITDA guidance and confirmed its revenue outlook, but a plasma customer's decision to move processing for 113 centers will reduce fourth-quarter results.
Q3 2026 revenue was $30.80 million, up 42.6%; pharma revenue rose 109.8% to $16.62 million, and plasma revenue rose 7.5% to $13.83 million.
GAAP net income was $6.74 million, or $0.11 per diluted share, versus $2.22 million, or $0.04 per diluted share, in Q3 2025.
Full-year 2026 guidance: net income $23.0 million to $24.0 million, diluted EPS $0.37 to $0.38, Adjusted EBITDA $38.5 million to $40.0 million; revenue outlook of $114.0 million to $117.0 million was confirmed.
A plasma customer will move payment processing for 113 centers to another provider by year-end; the estimated Q4 impact is $1.5 million in revenue and $700 thousand in gross profit.
Zeta Global reported third-quarter 2026 revenue of $493 million, up 46% from a year earlier, and GAAP net income of $38 million after a year-earlier net loss of $3.6 million. The company also raised its full-year 2026 revenue and GAAP EPS guidance, which gives shareholders a higher outlook than before the report.
Q3 2026 revenue was $493 million, up 46% year over year and $22 million above the guidance midpoint
Q3 2026 GAAP net income was $38 million and diluted GAAP EPS was $0.14, versus a net loss of $3.6 million in Q3 2025
Full-year 2026 revenue guidance raised to $1,853 million to $1,857 million, up $37 million at the midpoint from $1,818 million
Full-year 2026 GAAP EPS guidance raised to $0.22 to $0.24, up $0.13 at the midpoint from $0.09 to $0.11
Radiant Logistics reported results for the three months ended September 30, 2026, with revenue of $279.8 million, up 23.4%, and net income attributable to the company of $6.1 million, or $0.13 per share, compared with $1.3 million, or $0.03 per share, a year earlier. Adjusted EBITDA, a non-GAAP measure, rose to $12.2 million from $6.8 million, and the company reported no net debt at quarter end, which matters to shareholders because profit and balance sheet figures both improved.
Revenues of $279.8 million, up $53.1 million or 23.4% from $226.7 million a year earlier.
Net income attributable to Radiant Logistics of $6.1 million, or $0.13 per share, versus $1.3 million, or $0.03 per share.
Adjusted EBITDA of $12.2 million versus $6.8 million; adjusted EBITDA margin of 17.7% versus 11.4%.
Credit facility amended to extend maturity to August 7, 2031; $25.0 million outstanding against $27.8 million of cash at September 30, 2026.
Annexon reported a third-quarter 2026 net loss attributable to common stockholders of $51.2 million, or $0.25 per share, compared with $54.9 million, or $0.37 per share, a year earlier. Lower research and development spending more than offset higher general and administrative costs, and the company said its $213.4 million in cash and short-term investments should fund operations into 2028. Weighted-average shares rose to about 204.7 million from about 149.1 million, so per-share losses reflect a larger share base.
Net loss attributable to common stockholders was $51.2 million, or $0.25 per share, for the quarter ended September 30, 2026, versus $54.9 million, or $0.37 per share, a year earlier.
R&D expenses were $41.4 million, down from $49.7 million; G&A expenses rose to $10.9 million from $7.3 million.
Cash, cash equivalents and short-term investments were $213.4 million at September 30, 2026, which the company expects to fund operations into 2028.
The company entered a credit facility of up to $200 million with Oxford Finance LLC, drawing an initial $50 million at closing.
RAVE Restaurant Group reported first-quarter fiscal 2027 results for the period ended September 27, 2026. Revenue and net income rose from a year earlier, but comparable store sales fell at both Pizza Inn and Pie Five, and the company no longer expects five new restaurants from a ten-unit development deal to open this fiscal year.
Total revenue was $3.3 million, up 3.4% from the prior-year quarter; net income was $0.7 million, up 3.1%.
Diluted net income per share was $0.05, unchanged from the prior year; Adjusted EBITDA was $0.8 million, also unchanged.
Pizza Inn domestic comparable store retail sales fell 4.2%, and Pie Five fell 18.2%.
Cash and short-term investments totaled $14.8 million at September 27, 2026, and the company reported no debt.
Forward Air reported third quarter 2026 operating revenues of $674 million, up from $632 million a year earlier, and operating income of $44 million versus $15 million. Net income attributable to Forward Air was $11.4 million, or $0.34 per diluted share, compared with a loss of $16.3 million, or $0.52 per share, in the prior-year quarter. Nine-month results were hurt by a $244.0 million goodwill impairment, and quarterly operating cash flow fell 33.0%.
Operating revenues were $673.9 million for the quarter ended September 30, 2026, up 6.7% from $631.8 million.
Operating income was $43.9 million versus $15.0 million; net income attributable to Forward Air was $11.4 million, or $0.34 per diluted share, versus a loss of $0.52 per share.
Nine-month operating loss was $137.0 million, including a $244.0 million goodwill impairment.
Quarterly net cash from operating activities fell 33.0% to $35.3 million; free cash flow was $33.3 million versus $48.9 million.
Marygold Companies reported results for the fiscal first quarter ended September 30, 2026. Revenue rose to $9.4 million from $5.2 million a year earlier, and net income was $1.8 million, or $0.04 per share, compared with a net loss of $0.4 million, or $0.01 per share. The company also disclosed a pending definitive merger agreement under which funds managed by Madison Dearborn Partners would acquire all outstanding shares for $2.00 per share.
Revenue of $9.4 million for the quarter, up from $5.2 million a year earlier, excluding $1.5 million from discontinued New Zealand operations
Net income of $1.8 million, or $0.04 per share, versus a net loss of $0.4 million, or $0.01 per share, a year earlier
USCF Investments average assets under management rose to $5.5 billion from $2.9 billion a year earlier
Pending merger at $2.00 per share by Madison Dearborn Partners, expected to close in the first half of 2027 or earlier
KALA BIO reported preliminary, unaudited results for the quarter ended September 30, 2026, showing a net loss of approximately $0.8 million, down from $7.6 million a year earlier. Cash, cash equivalents and short-term investments were approximately $7.0 million with no debt, and the company expects to file its Form 10-Q on or about November 16, 2026. Final results may differ from these preliminary figures, which shareholders should weigh against the pending review.
Q3 2026 net loss of approximately $0.8 million vs. $7.6 million in Q3 2025
Nine-month 2026 net loss of approximately $4.0 million vs. $27.7 million in the same period of 2025
Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
Form 10-Q expected on or about November 16, 2026; results remain preliminary and unaudited
Telos Corporation reported third quarter 2026 revenue of $55.2 million, up from $51.4 million a year earlier, and GAAP net income of $4.4 million, or $0.06 per diluted share, compared with a net loss of $2.1 million a year earlier. The company also raised its full-year 2026 revenue and adjusted EBITDA outlook, which points to stronger results for shareholders.
Q3 2026 revenue was $55.2 million, versus $51.4 million in Q3 2025.
GAAP net income was $4.4 million ($0.06 per diluted share), compared with a net loss of $2.1 million ($0.03 per share) a year earlier.
Full-year 2026 revenue outlook was raised to $198.2 million-$200.7 million from $187 million-$195 million.
Full-year 2026 adjusted EBITDA outlook was raised to $32.3 million-$34.1 million from $23.6 million-$28.6 million.
United-Guardian reported higher third-quarter 2026 results, with net sales up 54% to $3,494,780 and net income up 247% to $930,912, or $0.20 per share. For the first nine months, net sales rose 25% to $9,475,269 and net income rose 70% to $2,478,393, or $0.54 per share, showing growth in both periods for shareholders.
Q3 2026 net sales were $3,494,780, up 54% from $2,264,261 in Q3 2025.
Q3 2026 net income was $930,912 ($0.20 per share), up 247% from $268,441 ($0.06 per share).
Nine-month 2026 net sales were $9,475,269, up 25%; net income was $2,478,393 ($0.54 per share), up 70%.
Pharmaceutical sales grew 29% in the quarter, driven primarily by Renacidin; cosmetic ingredient sales rose 187%.
Mereo BioPharma reported a third-quarter 2026 net loss of $5.9 million, down from $7.0 million a year earlier, as research and development and general and administrative expenses fell and the company recorded $800 thousand of revenue versus none a year earlier. Cash and cash equivalents were $26.1 million at September 30, 2026, which the company says should fund operations into late 2027, excluding any potential option payments from Sentynl Therapeutics.
Q3 2026 net loss was $5.9 million, compared with $7.0 million in Q3 2025; nine-month net loss was $19.6 million versus $34.5 million a year earlier.
Q3 2026 revenue was $800 thousand, compared with no revenue in Q3 2025; R&D expenses fell to $2.1 million from $4.3 million and G&A expenses fell to $4.9 million from $6.0 million.
Cash and cash equivalents were $26.1 million at September 30, 2026, down from $41.0 million at December 31, 2025.
Sentynl's exercise of its alvelestat option would bring $40 million in upfront and R&D payments; Mereo expects to provide an FDA-related update before the end of 2026.
ADC Therapeutics reported third quarter 2026 results, with net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million, or $0.16 per share, versus $41.0 million, or $0.30 per share, in the prior-year quarter. Cash and cash equivalents were $189.2 million at September 30, 2026, down from $261.3 million at December 31, 2025, and the company said its October 2026 financing restructuring extends its expected cash runway into 2029.
Q3 2026 net product revenue was $21.0 million, compared with $15.8 million in Q3 2025; license revenue and royalties were $0.7 million in both periods.
Q3 2026 net loss was $25.3 million ($0.16 per share), compared with $41.0 million ($0.30 per share) a year earlier; adjusted net loss was $8.8 million.
Cash and cash equivalents were $189.2 million at September 30, 2026, versus $261.3 million at December 31, 2025.
October 2026 restructuring included an $86.6 million PIPE financing, elimination of a $150 million change-of-control payment, and a reduction of the senior secured loan principal by $68.5 million to $50 million.
RB Global reported third-quarter 2026 results with revenue up 17% year over year to $1.3 billion and net income up 47% to $140.2 million, helped by a one-time $18.2 million excise tax refund. The company raised its full-year 2026 GTV growth outlook to 14% to 15% from 9% to 11% and narrowed its adjusted EBITDA range to $1,525 million to $1,545 million from $1,495 million to $1,545 million, while also declaring a $0.33 quarterly dividend.
Diluted EPS was $0.70, up 63%; diluted adjusted EPS was $1.03, up 11%
Full-year 2026 GTV growth outlook raised to 14% to 15% from 9% to 11%; adjusted EBITDA low end raised to $1,525 million
Repurchased about 3.9 million shares for $350.0 million in the quarter; $500.0 million remained under the NCIB as of September 30, 2026
Quarterly dividend of $0.33 per share payable December 17, 2026, to holders of record November 25, 2026
Air Industries Group reported results for the three and nine months ended September 30, 2026, in a press release furnished under Item 2.02. Third-quarter net sales rose 41.1% and the company swung to net income from a loss a year earlier, though results include merger-related costs tied to its pending merger with Tenax Aerospace Acquisition, LLC.
Q3 2026 net sales were $14.6 million, up from $10.3 million in Q3 2025; net income was $946,000 versus a net loss of $44,000.
Nine-month net sales were $38.2 million, up 8.7%, and the net loss narrowed to $902,000 from $1.5 million.
Q3 operating costs included $539,000 of stock compensation and merger-related expenses, with $503,000 of merger-related expense.
The company cited October 2026 net sales of about $5.6 million and firm customer orders in backlog of $95.4 million.
AN2 Therapeutics reported third-quarter 2026 results, with net loss narrowing to $8.0 million from $9.4 million a year earlier as research and development and general and administrative expenses declined. The company reported $80.2 million in cash, cash equivalents and investments as of September 30, 2026, and projects that this will fund operations into 2029 under its current plan.
Q3 2026 net loss was $8.0 million ($0.17 per share), versus $9.4 million ($0.31 per share) in Q3 2025.
R&D expenses were $5.7 million, down from $7.0 million, and G&A expenses were $2.9 million, down from $3.0 million.
Cash, cash equivalents and investments totaled $80.2 million at September 30, 2026, which the company projects will sustain operations into 2029.
Global Phase 2 study of oral epetraborole in polycythemia vera is cleared in all planned jurisdictions, with enrollment expected to begin by year-end 2026.
Foghorn Therapeutics reported third-quarter 2026 net income of $58.2 million, compared with a net loss of $15.8 million a year earlier, on collaboration revenue of $83.5 million, up from $8.2 million. Most of the revenue increase came from a $74.1 million cumulative catch-up adjustment tied to updated estimated future costs for ending the FHD-909 and SMARCA2 selective degrader programs, so the result is largely a one-time accounting effect.
Diluted earnings per share were $0.80, compared with a loss of $0.25 per share in the prior-year quarter.
Research and development expenses fell to $18.8 million from $20.0 million, and general and administrative expenses fell to $5.8 million from $6.7 million.
A new $2.3 million restructuring cost line appeared in the quarter.
Cash, cash equivalents and marketable securities were $156.2 million at September 30, 2026, with cash runway into the second half of 2029.
Select Water Solutions reported third-quarter 2026 revenue of $412 million, up 28% from a year earlier, and net income of $22.9 million, compared with $2.3 million in the third quarter of 2025. The company guided fourth-quarter Adjusted EBITDA to $95 million to $100 million and raised its 2026 net capital expenditure outlook to about $300 million to $310 million, while reporting that it closed the Pilot Water acquisition after quarter end.
Revenue was $412 million, up $90 million or 28% year over year; Adjusted EBITDA was $93.5 million, up from $59.5 million a year earlier.
Fourth-quarter 2026 Adjusted EBITDA is expected to be $95 million to $100 million; 2026 net capital expenditures are now expected to be about $300 million to $310 million.
After quarter end, the company issued $900 million of 7.625% senior notes due November 1, 2034, and entered a new $500 million revolving credit facility that was undrawn as of November 9, 2026.
Editas Medicine reported third quarter 2026 results, with a net loss attributable to common stockholders of $23.4 million, or $0.15 per share, down from $25.1 million, or $0.28 per share, a year earlier. Collaboration revenue rose to $10.4 million from $7.5 million, driven mainly by partner milestone revenue, while research and development and general and administrative expenses also increased. The company said its cash runway extends into the second half of 2028.
Net loss attributable to common stockholders was $23.4 million, or $0.15 per share, for the three months ended September 30, 2026, versus $25.1 million, or $0.28 per share, a year earlier.
Collaboration and other research and development revenues increased to $10.4 million from $7.5 million, mainly from milestones achieved by a strategic partner.
Cash, cash equivalents, and marketable securities were $190.2 million as of September 30, 2026, up from $146.6 million at December 31, 2025, and are expected to fund operations into the second half of 2028.
Editas received Australian ethics and regulatory approval to start the Phase 1/2 Strive study of EDIT-401, with initial safety and tolerability data expected in the first quarter of 2027.
GCM Grosvenor reported third quarter 2026 results, with GAAP net income attributable to the company up 17% to $12.3 million and fee-related earnings up 15% to $53.9 million from a year earlier. The company also approved a $0.12 per share dividend payable December 15, 2026, to holders of record on December 1, 2026.
Q3 2026 GAAP revenue was $145.6 million, up 8% year over year; adjusted net income rose 20% to $44.6 million.
Diluted earnings per share of Class A common stock were $0.17, up 6% from $0.16 a year earlier.
Fee-paying assets under management reached $78 billion, up 11%, and the company raised $2.7 billion of new capital in the quarter.
$54.1 million remained under the share repurchase authorization as of September 30, 2026.
Via Transportation reported third-quarter 2026 revenue of $143.5 million, up 31% from a year earlier, and a net loss of $18.8 million, down from $36.9 million. The company also issued fourth-quarter and full-year 2026 revenue outlook ranges, with full-year platform revenue expected at $556.7 million to $558.4 million.
Q3 2026 revenue was $143.5 million, up 31% from $109.7 million in Q3 2025.
Net loss per share was $0.23, compared with $1.49 a year earlier; Adjusted Net Loss per share was $0.00 versus $0.37.
Adjusted EBITDA was a loss of $3.2 million, compared with a loss of $8.7 million in Q3 2025.
Q4 2026 platform revenue is expected at $150.0 million to $151.7 million, and FY 2026 at $556.7 million to $558.4 million.
Constellation Energy reported third quarter 2026 results, with GAAP net income of $1.84 billion, or $5.19 per share, up from $930 million, or $2.97 per share, a year earlier. The company raised the midpoint of its full-year adjusted operating earnings guidance and narrowed the range to $12.50 to $12.80 per share, which signals stronger expected profit for shareholders.
Q3 2026 adjusted operating earnings were $5.06 per share, compared with $3.04 per share in Q3 2025
Q3 2026 operating revenues were $9.55 billion, compared with $6.57 billion in Q3 2025
Full-year 2026 adjusted operating earnings guidance narrowed to $12.50 to $12.80 per share, with the midpoint raised
Agreed to acquire the Rhode Island State Energy Center from Shell Energy North America for $715 million
NRG reported third-quarter 2026 GAAP net income of $561 million, up from $152 million a year earlier, and Adjusted EBITDA of $2,013 million, up from $1,205 million. The company reaffirmed its 2026 guidance, initiated 2027 guidance, and agreed to sell six gas-fired generation assets totaling 4.9 GW to LS Power for $4 billion in cash, with closing expected in the second quarter of 2027.
Q3 2026 GAAP EPS (basic) was $2.59 versus $0.70 a year earlier; Adjusted EPS was $4.68 versus $2.78.
2026 guidance reaffirmed, including Adjusted EPS of $7.90 to $9.90 and Adjusted EBITDA of $5,325 million to $5,825 million.
2027 guidance initiated, with Adjusted EPS of $8.05 to $10.05; the 2027 plan includes $1 billion of share repurchases and an 8% dividend increase to $2.05 per share.
The 4.9 GW sale to LS Power is for $4 billion in cash, subject to closing adjustments and approvals including HSR, FERC and the NYSPSC.
Abeona reported third-quarter 2026 results, with net ZEVASKYN revenue of $13.5 million, up 18% from $11.4 million in the second quarter, and a net loss of $4.8 million, or $0.08 per share, compared with $20.2 million, or $0.35 per share, in the prior quarter. The company also announced the $20 million stock-based acquisition of ABO-801 and a $30 million private placement, which it said will fund pipeline development and ZEVASKYN commercialization.
Net ZEVASKYN revenue was $13.5 million in Q3 2026, up 18% from $11.4 million in Q2 2026; one treatment's revenue was not recognized because its batch did not meet the identity assay release criterion.
Net loss was $4.8 million ($0.08 per share) in Q3 2026, versus $20.2 million ($0.35 per share) in Q2 2026.
Cash, cash equivalents and short-term investments were $134.9 million at September 30, 2026, down from $146.8 million at June 30, 2026; the figure excludes the $30 million private placement completed after quarter end.
Abeona issued $20 million of common stock to Ellodi Pharmaceuticals for the ABO-801 asset, with no upfront cash, plus up to $60 million in additional milestone payments and royalties.
Kodiak Gas Services reported third quarter 2026 net income attributable to common shareholders of $71.5 million, or $0.70 per diluted share, compared with a net loss of $14.0 million a year earlier. The company also raised its full-year 2026 adjusted EBITDA and discretionary cash flow guidance, reflecting higher revenue and the DPS acquisition, which closed April 1, 2026.
Total revenues were $401.8 million, up from $322.7 million in the third quarter of 2025.
Net income attributable to common shareholders was $71.5 million, or $0.70 per diluted share, versus a loss of $14.0 million, or $0.17 per share, a year earlier.
Full-year 2026 adjusted EBITDA guidance was raised to $840 million to $860 million; discretionary cash flow guidance rose to $580 million to $600 million.
The quarterly dividend was $0.51 per share, and the share repurchase program was extended to December 31, 2027, with about $31.7 million available.
National Energy Services Reunited (NESR) reported third-quarter 2026 results with revenue of $504.7 million, up 70.9% from a year earlier, and net income of $34.3 million, up 93.5%. Both figures were lower than the June 2026 quarter, which the company attributed to changing activity levels in its hydraulic fracturing, well testing and wireline logging services. The board also declared a quarterly cash dividend of $0.10 per share.
Revenue was $504.7 million, up 70.9% year-over-year but down 3.1% from $520.8 million in the June 30, 2026 quarter.
Diluted EPS was $0.33, compared with $0.18 a year earlier and $0.43 in the June quarter.
Adjusted EBITDA was $95.9 million, up 49.9% year-over-year.
The board declared a $0.10 per share cash dividend payable December 10, 2026, to holders of record on December 3, 2026.
QXO said preliminary, unaudited third quarter 2026 net sales were approximately $4.90 billion, up 79% from $2.73 billion a year earlier, and adjusted EBITDA was approximately $557 million, up 85% from $301 million. GAAP net loss was approximately $123 million, compared with $139 million in the third quarter of 2025, and the company said the figures may change before it reports full results on November 12, 2026.
Net sales: approximately $4.90 billion, up 79% from $2.73 billion in Q3 2025
GAAP net loss: approximately $123 million, versus $139 million a year earlier
Adjusted EBITDA (non-GAAP): approximately $557 million, up 85% from $301 million; margin 11.4% versus 11.1%
Results include Kodiak Building Partners from April 1, 2026 and TopBuild Corp. from July 1, 2026; full results due November 12, 2026
Greif reported fourth-quarter and fiscal 2026 results for the year ended September 30, 2026. Full-year net income rose to $261.5 million, and Adjusted EBITDA rose 11.7%, while fourth-quarter Adjusted EBITDA fell 3.1% to $163.0 million and Adjusted free cash flow of $279.3 million was below the company's most recent guidance range. The company also gave fiscal 2027 low-end guidance of $645 million Adjusted EBITDA and $290 million Adjusted free cash flow.
Fiscal 2026 net income was $261.5 million, or $4.54 per diluted Class A share, versus $31.6 million, or $0.55, a year earlier.
Fourth-quarter net loss narrowed to $6.5 million, or $0.11 per diluted Class A share, from a net loss of $24.3 million, or $0.42, a year earlier.
Company will close its Sweetwater paperboard mill in Austell, GA, and has achieved $105 million in cumulative run-rate cost savings, with a new target of $150 million by the end of fiscal 2027.
Fiscal 2027 low-end guidance: Adjusted EBITDA of $645 million and Adjusted free cash flow of $290 million.
Hyster-Yale reported third-quarter 2026 revenue of $827 million, up from $813 million in the second quarter, and narrowed its operating loss to $9 million from $18 million. The company said it expects Q4 2026 revenue to grow sequentially on higher shipments, but tariff-related costs remain elevated and the company plans new cost-reduction programs targeting at least $100 million at maturity in 2029.
Q3 2026 revenue was $827 million versus $813 million in Q2 2026; net loss narrowed to $15 million from $32 million
Operating loss was $9 million in Q3 2026 versus an operating profit of $2.3 million in Q3 2025
Company expects Q4 2026 bookings to exceed Q4 2025 and Q3 2026, with sequential revenue growth
New programs targeting at least $100 million of cost reductions and mitigations at maturity, expected in 2029
Biglari Holdings reported third-quarter 2026 net earnings of $1.0 million, compared with a net loss of $5.3 million a year earlier. Pre-tax operating earnings rose to $9.9 million from $6.9 million, though the company said its investment gains and losses also affect reported results.
Q3 2026 pre-tax operating earnings were $9,874 thousand, up from $6,854 thousand in Q3 2025.
Nine-month 2026 net earnings were $26,409 thousand, up from $12,365 thousand in the same period of 2025.
Nine-month 2026 pre-tax operating earnings were $12,007 thousand, down from $20,521 thousand a year earlier.
Steak n Shake same-store sales rose 18.2% in Q3 2026 for domestic company-operated and franchise-partner-operated restaurants.
York Water reported third quarter 2026 operating revenues of $24,333,000, up $3,972,000 from a year earlier, and net income of $7,809,000, up $1,608,000. Nine-month revenues rose to $67,922,000 and net income to $20,238,000, both higher than in the same period of 2025, mainly due to rate increases effective March 1, 2026. Both headline measures improved, which points to stronger results for shareholders.
Q3 2026 operating revenues $24,333,000 vs. $20,361,000 in Q3 2025; net income $7,809,000 vs. $6,201,000
Q3 2026 basic and diluted EPS $0.48, up from $0.43 a year earlier
Company estimates an additional $11.8 million of 2026 investment, excluding acquisitions
OneMedNet said it expects preliminary third-quarter 2026 revenue of about $1 million, up 242% from the prior quarter and 465% from the year-earlier quarter. It also guided to fourth-quarter 2026 revenue of $12 million to $14 million, pending customer acceptance of delivered data by quarter-end. The third-quarter figures remain preliminary and may change before the Form 10-Q, expected by November 16, 2026.
Preliminary Q3 2026 revenue of about $1 million for the quarter ended September 30, 2026, up 242% from the prior quarter and 465% from Q3 2025.
Q4 2026 revenue guidance of about $12 million to $14 million, pending customer acceptance of delivered data by quarter-end.
Q3 results are preliminary and subject to adjustment; the Form 10-Q is expected by November 16, 2026.
Franklin Templeton announced preliminary fourth quarter and full-year results for the period ended September 30, 2026, reporting a quarterly net income of $380.1 million, or $0.72 per diluted share, alongside $20.8 billion in long-term net inflows. Total assets under management reached $1.795 trillion, reflecting an 8% increase year-over-year.
Preliminary fourth quarter net income was $380.1 million, or $0.72 per diluted share, compared to $117.6 million, or $0.21 per diluted share, in the prior-year period.
Long-term net inflows were $20.8 billion for the quarter ended September 30, 2026, and $84.1 billion for the full fiscal year.
Total assets under management were $1.795 trillion as of September 30, 2026.
The company repurchased 2.5 million shares of its common stock for $86.1 million during the fourth quarter.
Global Partners LP reported third-quarter 2026 net income of $52.4 million, or $1.26 per diluted common unit, compared with $29.0 million, or $0.66 per unit, a year earlier, while sales rose to $6.7 billion from $4.7 billion. The company said stronger Wholesale results more than offset lower retail fuel volumes, and it declared a $0.7850 per unit distribution payable November 13, 2026. The filing also says the credit agreement was extended to October 16, 2031.
Diluted earnings per common unit were $1.26 versus $0.66; net income was $52.4 million versus $29.0 million.
Adjusted EBITDA was $122.9 million versus $98.8 million; distributable cash flow was $70.1 million versus $53.0 million.
Wholesale product margin rose to $111.4 million from $78.0 million, while GDSO product margin fell to $210.6 million from $218.9 million, and GDSO gasoline volume was 361.3 million gallons versus 390.8 million.
Distribution of $0.7850 per unit is payable November 13, 2026 to holders of record on November 9, 2026; the credit facility maturity was extended to October 16, 2031.
Georgia Banking Company filed an investor presentation with its third-quarter 2026 results, its first full quarter of combined operations with Tandem Bancorp, which closed June 1, 2026. Net interest income rose 8.0% from the second quarter to $31.4 million, while noninterest income fell 13.8% to $2.8 million and net interest margin declined to 4.17%.
Diluted EPS of $0.57 and operating EPS of $0.74 for the quarter; ROTCE 9.70% and operating ROTCE 12.41%
Net interest income $31.4 million, up 8.0% from 2Q26; NIM down 14 basis points, which the company attributed to higher cost of refinanced subordinated debt
Noninterest income $2.8 million, down 13.8% from 2Q26, due to lower retail mortgage originations
CET1 ratio 10.59% at quarter end, up from 10.29% in 2Q26; management plans to use the presentation in investor meetings beginning November 9, 2026
Strive reported GAAP net income of $509.0 million for the quarter ended September 30, 2026, compared with losses in the comparable 2025 periods. The filing attributes the result to a $533.7 million net unrealized gain on digital assets, while total revenues were $2.7 million. Shareholders should note the gain is a fair value adjustment on bitcoin, not operating income.
GAAP net income was $509.0 million, or $5.24 per diluted share, for the three months ended September 30, 2026; non-GAAP adjusted net income attributable to common stockholders was $494.6 million, or $5.46 per diluted share.
Net unrealized gain on digital assets was $533.7 million; total operating expenses were $38.7 million.
Strive acquired 8,136 bitcoin in the third quarter and 15,124 bitcoin from October 1 through October 30, 2026.
On October 20, 2026, Strive completed an offering of 7,000,000 SATS shares for net proceeds of approximately $609.0 million; cash and cash equivalents were $490.4 million as of October 30, 2026.
Aligos Therapeutics reported third quarter 2026 results on November 6, 2026, with a net loss of $21.9 million, down from $31.5 million a year earlier, as revenue rose and research and development spending fell to $18.9 million. Cash, cash equivalents and investments of $31.1 million are expected to fund planned operations only into the first quarter of 2027.
Net loss for the three months ended September 30, 2026 was $21.9 million, or $(2.09) per share, versus $31.5 million, or $(3.04) per share, a year earlier.
Revenue from customers was $2.8 million, up from $0.7 million, and licensing revenue was $39 thousand, compared with none in the prior-year quarter.
Cash, cash equivalents and investments totaled $31.1 million at September 30, 2026, down from $77.8 million at December 31, 2025.
Topline data from the Phase 2 B-SUPREME study of pevifoscorvir sodium are expected in late Q3 2027.
PPL reported third-quarter 2026 GAAP earnings of $367 million, or $0.49 per share, compared with $318 million, or $0.43 per share, in the third quarter of 2025. The company also narrowed its full-year 2026 ongoing earnings forecast to a range of $1.92 to $1.96 per share and increased its long-term annual EPS growth target to 7% to 9% through at least 2030, supported by a $25 billion capital investment plan.
Announced third-quarter 2026 reported GAAP earnings of $0.49 per share on net income of $367 million.
Achieved third-quarter ongoing EPS of $0.54 compared to $0.48 in 2025.
Increased long-term annual EPS growth target to 7% to 9% through at least 2030.
Announced a $25 billion capital plan for 2027 to 2030, driving average annual rate base growth of 10%.
Sunstone Hotel Investors reported third-quarter 2026 net income attributable to common stockholders of $38.7 million, or $0.21 per diluted share, compared with a net loss of $2.9 million, or $(0.02) per share, a year earlier. The company raised its full-year 2026 guidance, including adjusted FFO per diluted share of $1.00 to $1.03, up from $0.93 to $0.98, and the quarter included a $31.5 million gain on sale of assets. For shareholders, the results and higher outlook reflect stronger hotel demand and continued stock repurchases, which the company says were completed at a discount.
Third-quarter RevPAR rose 11.4% to $235.22; Total RevPAR rose 10.5% to $394.97.
Adjusted FFO per diluted share rose 17.6% to $0.20; Adjusted EBITDAre rose 8.8% to $54.5 million.
2026 guidance raised: net income attributable to common per diluted share now $0.46 to $0.49 (prior $0.37 to $0.42); RevPAR growth now 9.5% to 10.5% (prior 7.0% to 9.0%).
From the start of 2026 through November 5, 2026, the company repurchased $196.9 million of common and preferred stock, with $310.6 million remaining under its authorization.
InTest reported third-quarter 2026 revenue of $35.1 million, up 34% from a year earlier but essentially flat sequentially, and net earnings of $1.9 million, or $0.15 per diluted share, versus a net loss a year earlier. Orders reached a record $49.4 million, lifting backlog to $59.7 million, and management guided fourth-quarter 2026 revenue to $34.0 million to $36.0 million.
Revenue of $35.1 million, up 33.7% year-over-year and down 0.7% from the second quarter of 2026
Net earnings of $1.9 million, or $0.15 per diluted share, versus a net loss of $0.9 million, or $(0.08), in the prior-year quarter
Orders of $49.4 million, up 31.3% year-over-year, led by Semi orders of $25.1 million; backlog of $59.7 million
Fourth-quarter 2026 outlook: revenue of $34.0 million to $36.0 million and gross margin of approximately 45%
Brookfield Asset Management reported third-quarter 2026 results for the period ended September 30, 2026. Fee-related earnings and distributable earnings each rose 15% from a year earlier, and the company raised $25 billion of capital during the quarter. The board also declared a quarterly dividend of $0.5025 per share.
Fee-related earnings were $864 million, or $0.54 per share, in the quarter, up from $754 million a year earlier.
Distributable earnings were $763 million, or $0.47 per share, in the quarter, up from $661 million a year earlier.
Net income was $3.0 billion in the quarter and $5.4 billion over twelve months, including a $2.0 billion non-cash gain on the Oaktree acquisition and consolidation.
Quarterly dividend of $0.5025 per share is payable December 31, 2026, to holders of record on November 30, 2026.
Ubiquiti reported results for the fiscal first quarter ended September 30, 2026, with revenue of $1,026.2 million, up 39.9% from a year earlier, and GAAP diluted EPS of $5.29, up from $3.43. The company also declared a $1.00 per share cash dividend, but warned that rising component costs and supply constraints could pressure gross margins and revenue.
Revenue of $1,026.2 million versus $733.8 million a year earlier; Enterprise Technology made up $941.3 million
GAAP net income of $320.5 million and GAAP diluted EPS of $5.29, versus $207.9 million and $3.43 a year earlier
Gross profit margin of 47.3%, up from 46.0% a year earlier, though the company cited higher component costs that may pressure margins
$1.00 per share cash dividend payable November 23, 2026, to shareholders of record on November 16, 2026
E.W. Scripps reported third-quarter 2026 revenue of $545 million, up 3.6% from a year earlier, and net income attributable to shareholders of $20.7 million, or 21 cents per share, compared with a loss of $49 million in the prior-year quarter. Political revenue of $82.6 million supported results, while Scripps Networks revenue fell 14%. For the nine months, the company reported a loss of $1.2 billion, including a $1.1 billion goodwill and intangible impairment, and it expects Local Media revenue to rise in the low-to-mid 40% range in the fourth quarter.
Q3 revenue $545 million, up $19 million or 3.6%; political revenue $82.6 million versus $5.5 million a year earlier
Q3 net income attributable to shareholders $20.7 million or 21 cents per share, including $18.8 million in restructuring costs
Nine-month loss attributable to shareholders $1.2 billion or $12.73 per share, including a $1.1 billion impairment for Scripps Networks
Cash of $83.4 million and total debt of $2.5 billion at Sept. 30; company plans to pay down at least $150 million of debt in Q4
Fluor Corporation announced its financial results for the third quarter ended September 30, 2026, reporting revenue of $3.7 billion and GAAP net earnings of $158 million. The company achieved record quarterly new awards of $10.9 billion, lifting backlog to $34.3 billion, and affirmed its full-year 2026 adjusted EBITDA guidance of $500 million to $525 million.
Revenue reached $3.7 billion for Q3 2026, up 10% year over year.
New awards totaled a record $10.9 billion in the quarter, including $7.5 billion for LNG Canada Phase 2.
Backlog increased 21% year over year to $34.3 billion as of September 30, 2026.
Share repurchases totaled $300 million during the quarter and $1.1 billion year to date.
Enbridge reported third-quarter 2026 GAAP earnings attributable to common shareholders of $1.3 billion, or $0.59 per share, up from $0.7 billion, or $0.30 per share, a year earlier, and adjusted earnings of $1.1 billion, or $0.49 per share, up from $0.46. The company reaffirmed its 2026 guidance and said CEO Greg Ebel will retire in January, with Michele Harradence to lead the company. All figures are in Canadian dollars.
Q3 GAAP earnings attributable to common shareholders of $1.3 billion ($0.59 per share) vs. $0.7 billion ($0.30) in Q3 2025; the increase was primarily due to non-cash, unrealized changes in the value of derivative financial instruments.
Q3 adjusted earnings of $1.1 billion ($0.49 per share) vs. $1.0 billion ($0.46) in Q3 2025; adjusted EBITDA of $4.4 billion vs. $4.3 billion.
2026 guidance reaffirmed: adjusted EBITDA of $20.2 billion to $20.8 billion and DCF per share of $5.70 to $6.10.
Greg Ebel is retiring in January; Michele Harradence will lead Enbridge.
Vistra Corp. reported third quarter 2026 net income of $1,140 million and ongoing operations adjusted EBITDA of $2,378 million, representing more than 50% growth year over year. The company raised and narrowed its full-year 2026 guidance, initiated 2027 guidance ranges, and authorized an additional $1.5 billion for share repurchases. Shareholders also saw the completed acquisition of Cogentrix Energy and the commencement of new solar operations.
GAAP third quarter 2026 Net Income reached $1,140 million, up from $652 million in the third quarter of 2025.
Ongoing Operations Adjusted EBITDA grew over 50% year over year to $2,378 million for the quarter.
Board of Directors authorized an additional $1.5 billion of share repurchases, expected to be used by year-end 2028.
2026 Ongoing Operations Adjusted EBITDA guidance range was narrowed and raised to $7.1 billion to $7.5 billion.
Moderna reported third-quarter 2026 revenue of $1.3 billion and net income of $0.2 billion, returning to a profit compared to a net loss in the same period last year. Driven by this performance and pipeline progress, the company raised its full-year 2026 revenue growth outlook to 15% to 25% and increased its expected year-end cash and investments balance to between $8.1 billion and $8.3 billion. Shareholders also received updates on positive Phase 3 data for intismeran in melanoma and the U.S. FDA approval of the mFLUSIVA vaccine.
Third-quarter 2026 total revenue grew 29% year-over-year to $1.3 billion, with GAAP net income of $162 million or $0.38 per diluted share.
Full-year 2026 expected revenue growth was raised to 15% to 25%, up from the previous expectation of up to 10% growth.
Year-end 2026 cash and investments are now projected to be $8.1 billion to $8.3 billion, bolstered by operational execution and a $2.6 billion net proceeds convertible notes offering.
Research and development expenses for 2026 are now expected to be approximately $2.7 billion, reduced from the prior estimate of approximately $2.9 billion.
Elanco Animal Health Inc reported third quarter 2026 revenue of $1.265 billion, representing an 11% increase year-over-year, and net income of $18 million. Driven by strong demand and gross margin expansion, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted earnings per share.
Third quarter revenue reached $1.265 billion, up 11% reported and 9% organic constant currency.
Reported net income was $18 million, while adjusted EPS was $0.27.
Full year 2026 revenue guidance was raised to $5.155 billion to $5.18 billion.
Net leverage ratio improved to 2.9x Adjusted EBITDA at the end of the third quarter.
Marcus & Millichap reported third quarter 2026 revenue of $208.4 million, up 7.5% from a year earlier, and net income of $1.0 million, or $0.03 per diluted share, compared with $0.2 million, or $0.01, in the third quarter of 2025. The company said the results are preliminary until it files its Form 10-Q, and it expects near-term challenges in the commercial real estate market to extend through 2026.
Total revenue was $208.4 million versus $193.9 million; brokerage commissions rose 7.4% to $174.1 million, with Middle Market and Larger Transaction Market brokerage revenue up 18.1%.
Adjusted EBITDA was $8.2 million versus $6.9 million; cost of services rose to 64.0% of total revenue, up 160 basis points.
Nine-month revenue was $582.8 million, up 14.0%, and nine-month net income was $1.8 million, or $0.05 per diluted share, compared with a net loss of $15.2 million.
The company repurchased 912,957 shares for $23.9 million in the first nine months and had about $90.1 million remaining under its repurchase program as of November 3, 2026.
Avalanche Treasury Corp (AVAT) reported preliminary, unaudited third-quarter 2026 net income of approximately $54.6 million, or $1.53 per diluted share, with about $60 million from market-driven changes in the value of its AVAX holdings and realized losses. It also repurchased about 8% of its Class A shares at an average price of $1.14 and repaid its FalconX loan in full, and the full third-quarter results are due in November 2026.
Preliminary Q3 2026 net income of approximately $54.6 million, or $1.53 per diluted share; approximately $60 million of gains from market-driven changes in AVAX value and realized losses
Repurchased 2,889,440 Class A shares at an average of $1.14 per share, about $3.3 million in total, roughly 8% of Class A shares outstanding as of August 24, 2026
Held 13.31 million AVAX tokens as of September 30, 2026, with about 60% unlocked; about 91% was staked in September 2026
Conference call on November 19, 2026 at 4:00 p.m. ET to discuss third-quarter results
Mount Logan Capital reported third-quarter 2026 total revenues of $12.9 million, up 12% from $11.4 million a year earlier, and a net loss of $3.7 million versus $13.4 million in the third quarter of 2025. Basic loss per share was $0.33, compared with $1.64, and the company attributed the narrower loss mainly to transaction expenses from the prior-year TURN merger that did not recur. Segment Income fell to $3.2 million in the quarter, but year-to-date Segment Income rose 21% to $11.5 million.
Total revenues $12.9 million for Q3 2026, up 12% from $11.4 million in Q3 2025
Net loss $3.7 million, compared with $13.4 million in Q3 2025; basic loss per share $0.33 versus $1.64
Q3 Segment Income $3.2 million versus $4.2 million; year-to-date Segment Income $11.5 million, up 21%
Quarterly distribution of $0.03 per share payable November 30, 2026 to holders of record on November 19, 2026
Comstock reported third-quarter 2026 revenue of $17.9 million, up 34% from a year earlier, and net income of $0.6 million, up 9%. Adjusted EBITDA more than doubled to $2.3 million, although the quarter included a $1.0 million unrealized loss on its Jericho Energy Ventures equity investments. Headline revenue and profit measures improved for both the quarter and the first nine months, but the quarter's net income absorbed that investment loss.
Q3 2026 revenue was $17.9 million versus $13.3 million in Q3 2025; Adjusted EBITDA was $2.3 million versus $1.1 million.
Q3 diluted EPS was $0.06 versus $0.05; year-to-date diluted EPS was $1.05 versus $0.34, with year-to-date net income of $11.4 million.
Q3 net income includes a $1.0 million unrealized loss on Jericho (JEV) equity investments, which partially reverses a significant Q2 gain; the year-to-date gain remains up $3.7 million.
Managed portfolio grew to 115 assets, up from 91 a year earlier, including 12 new ParkX contracts in Q3.
Regency Centers reported third quarter 2026 net income attributable to common shareholders of $75.1 million, or $0.41 per diluted share, alongside Nareit FFO of $1.23 per diluted share. The company raised its full-year 2026 Core Operating Earnings guidance midpoint and increased its quarterly common stock dividend by 6% to $0.800 per share. Shareholders experienced higher year-over-year Same Property NOI growth and strong leasing spreads during the quarter.
Reported Q3 2026 Net Income Attributable to Common Shareholders of $75.1 million, or $0.41 per diluted share.
Raised full year 2026 Core Operating Earnings guidance range to $4.65 to $4.67 per diluted share.
Increased quarterly common stock cash dividend by 6% to $0.800 per share.
Same Property NOI increased year-over-year by 5.1% for the third quarter of 2026.
Tianci International reported fiscal 2026 results for the year ended July 31, 2026, in Exhibit 99.1 to this 8-K. Total revenue rose to $14,242,611 from $9,282,997, helped by $4,409,563 in first-year mineral sales, and the net loss narrowed to $2,454,798 from $2,686,357. Logistics revenue fell 0.7% and its gross profit percentage dropped to 2.29%, so the core business weakened even as total results improved.
Total revenue of $14,242,611 for the year ended July 31, 2026, versus $9,282,997 a year earlier.
Mineral sales, a new business, contributed $4,409,563 at a 7.43% gross profit percentage.
Net loss of $2,454,798 versus $2,686,357 in fiscal 2025; operations used $2,199,382 in cash.
A public offering completed in June 2026 produced net proceeds of $4,390,512.
Tucows reported third-quarter 2026 revenue of $100.0 million, up 1.4% from a year earlier, and a net loss of $10.3 million, down from $23.0 million in the third quarter of 2025. Gross profit and Adjusted EBITDA rose, but the company said gross profit was driven mainly by a large, non-recurring rate adjustment from renegotiating its mobile contract, and cash and restricted cash fell to $41.0 million from $60.2 million at the end of the second quarter.
Revenue of $100.0 million, up 1.4% year over year, driven by revenue growth at Ting.
Net loss of $10.3 million, or $(0.92) per share, versus a net loss of $23.0 million, or $(2.08) per share, in Q3 2025.
Adjusted EBITDA of $18.6 million, up 39.8% year over year, mainly due to the mobile contract re-rate in the Corporate segment.
Cash and restricted cash of $41.0 million at September 30, 2026, down from $60.2 million at June 30, 2026.
Diodes reported third quarter 2026 revenue of $532.6 million, up 35.8% from a year earlier, with GAAP net income of $43.7 million, or $0.95 per diluted share, versus $0.31 a year earlier. The company expects fourth quarter revenue of about $550 million, plus or minus 3%, and non-GAAP adjusted EPS of $1.35, plus or minus $0.10. The results are preliminary and unaudited and remain subject to revision until the Form 10-Q is filed.
Q3 2026 revenue $532.6 million, up 35.8% from $392.2 million in Q3 2025
GAAP EPS $0.95 per diluted share vs $0.31 in Q3 2025; non-GAAP EPS $1.18 vs $0.37
Q4 2026 outlook: revenue about $550 million (plus or minus 3%); non-GAAP EPS $1.35 (plus or minus $0.10)
Private placement of 0.00% Convertible Senior Notes due 2031 totaling $375 million
NeOnc reported third-quarter 2026 results, with its net loss falling to $4.4 million from $8.6 million in the year-earlier quarter and total operating expenses declining to $5.8 million from $6.9 million. Cash and cash equivalents rose to $6.2 million at September 30, 2026, helped by a September registered direct offering of approximately $15 million gross, and the company said it will present NEO100 and NEO212 data on November 13, 2026.
Net loss attributable to common stockholders was $7.3 million, or $(0.28) per share, versus $8.6 million, or $(0.45) per share, in Q3 2025; the figure includes $2.8 million of noncash deemed dividends.
Cash and cash equivalents were approximately $6.2 million at September 30, 2026, up from approximately $2.0 million at June 30, 2026.
R&D expenses were $1.3 million, compared with $0.7 million in Q3 2025, while G&A expenses fell to $0.6 million from $0.9 million.
Data from NEO100 and NEO212 will be presented in two posters on November 13, 2026, at the Society for Neuro-Oncology Annual Meeting in Philadelphia.
PodcastOne said it expects record first-half revenue of $31.5 million and Adjusted EBITDA of $3.0 million, up 76% year over year, for the six months ended September 30, 2026. Second-quarter revenue is expected to be $15.2 million with Adjusted EBITDA of $1.4 million. These figures are preliminary, unaudited and subject to change, and the company's board has formed a special committee to evaluate inbound strategic interest, which may or may not lead to a transaction.
Expected first-half revenue of $31.5 million and Adjusted EBITDA of $3.0 million, up 76% year over year
Expected second-quarter revenue of $15.2 million and Adjusted EBITDA of $1.4 million
Special committee of independent directors formed after inbound interest from multiple strategic parties, first announced October 28; company intends to retain a financial advisor
Figures are preliminary and unaudited, not reviewed by MGO; no GAAP net income reconciliation was provided
Helios Technologies reported third-quarter 2026 net sales of $230 million, up 4% from the prior-year period, and GAAP diluted EPS of $0.53, up 71% from $0.31. The company raised its full-year 2026 sales outlook to $895 million to $902 million from $880 million to $900 million, while narrowing its adjusted EBITDA margin and adjusted diluted EPS ranges.
Q3 2026 net sales were $229.7 million, up 4%; the company cited 13% growth on a pro forma basis
Q3 GAAP diluted EPS was $0.53 versus $0.31; adjusted diluted EPS was $0.80, up 11%
FY2026 sales outlook raised to $895 million to $902 million; adjusted diluted EPS range narrowed to $3.08 to $3.15
Q4 2026 outlook: sales of $205 million to $212 million and adjusted diluted EPS of $0.60 to $0.67
Turtle Beach reported third-quarter 2026 net revenue of $84.7 million, up 5.3% from $80.5 million a year earlier, and net income of $4.4 million versus $1.7 million. The company reaffirmed its full-year 2026 net revenue guidance of $335 million to $355 million and adjusted EBITDA guidance of $44 million to $48 million, and said it expects capacity to resume share repurchases after the holiday season.
Q3 net revenue was $84.7 million, up 5.3% from $80.5 million; diluted EPS was $0.24 versus $0.08
Adjusted EBITDA was $8.1 million versus $11.0 million a year earlier; gross margin was 34.9%
Full-year 2026 guidance reaffirmed: net revenue $335 million to $355 million, adjusted EBITDA $44 million to $48 million
Nine-month net loss was $18.1 million; inventory rose to $79.8 million, up $23.2 million from the second quarter
Hyperliquid Strategies Inc (PURR) reported net income of $620.6 million for the quarter ended September 30, 2026. The filing says most of that figure came from $803.0 million in net unrealized gains on its HYPE token holdings, and it also included a $172.3 million income tax provision. The company also said it raised $911 million in equity and deployed $802 million, mainly to buy HYPE tokens, and that it has filed an application to become a futures commission merchant.
Net income of $620.6 million for the quarter, including $803.0 million in net unrealized gains on HYPE tokens and a $172.3 million provision for income taxes
Quarter-end HYPE holdings of 38.5 million tokens, up from 29.3 million at June 30, 2026, after 9.1 million tokens were bought for $785 million
Raised $911 million under its committed equity facility and reported $254.6 million in cash and cash-like instruments with zero debt
Stockholders approved on November 4, 2026 the issuance of shares under the ChEF Purchase Agreement above 19.99% of common stock, with 81,436,539 votes for
Pangaea Logistics Solutions reported third-quarter 2026 results, with GAAP net income attributable to the company of $38.3 million, or $0.59 per share, up from $12.2 million, or $0.19 per share, a year earlier. Total revenue was $219.1 million, and Adjusted EBITDA rose 81.3% to $52.4 million, which matters to shareholders because it shows a large year-over-year gain in earnings and cash generation. The board also declared a $0.10 quarterly dividend.
GAAP net income attributable to Pangaea of $38.3 million, or $0.59 per share, versus $12.2 million, or $0.19 per share, in Q3 2025
Total revenue of $219.1 million versus $168.7 million in Q3 2025; Adjusted EBITDA of $52.4 million, a 23.9% margin versus 17.1%
Average TCE rate of $20,414 per day versus $15,559 per day a year earlier; the company reported cash and equivalents of $144.9 million at September 30, 2026
Quarterly dividend of $0.10 per share, payable December 15, 2026, to holders of record on December 1, 2026
Consolidated Edison reported third-quarter 2026 net income of $766 million, or $2.07 per share, up from $688 million, or $1.91 per share, in the third quarter of 2025. The company also narrowed its full-year 2026 adjusted earnings per share guidance range to between $6.05 and $6.15.
Q3 2026 net income was $766 million ($2.07 per share) compared to $688 million ($1.91 per share) in Q3 2025.
First nine months of 2026 net income reached $1,998 million ($5.44 per share) versus $1,726 million ($4.84 per share) for the same period in 2025.
Full-year 2026 adjusted EPS guidance was narrowed to a range of $6.05 to $6.15 per share.
The company plans to invest approximately $797 million in climate resilience from 2026 through 2030.
Chesapeake Utilities reported third-quarter 2026 net income of $21.6 million, or $0.89 per diluted share, up from $19.4 million, or $0.82, a year earlier. The company also reaffirmed its 2026 capital expenditure guidance and its 2028 earnings guidance of $7.75 to $8.00 per share, and said it will joint venture 49 percent of the $1.2 billion Florida Energy Pathway project with NextEra Energy Resources. Shareholders may be affected by the planned equity program of up to $225 million.
Q3 2026 operating revenues were $195.8 million, up from $179.6 million; net income was $21.6 million versus $19.4 million
Nine-month 2026 diluted EPS was $4.40, up from $4.03 a year earlier
Joint venture with NextEra Energy Resources to finance and own 49 percent of the $1.2 billion, 97-mile Florida Energy Pathway project
New at-the-market equity program allows issuance and sale of up to $225 million of common stock; 2026 capital expenditure guidance of $550 to $600 million affirmed
Concentra Group Holdings Parent, Inc. reported its third quarter 2026 financial results, highlighting an 8.6% increase in revenue to $622.1 million and a 36.0% increase in net income to $67.8 million compared to the same period in 2025. Driven by this performance, the company raised its full-year 2026 financial guidance, declared a cash dividend of $0.0625 per share, and authorized a new $250 million share repurchase program.
Revenue for the third quarter of 2026 reached $622.1 million, up 8.6% year over year.
Net income for the quarter rose 36.0% to $67.8 million, with basic and diluted earnings per share at $0.52.
The board of directors declared a cash dividend of $0.0625 per share, payable on or about December 4, 2026.
A new share repurchase program was authorized to buy back up to $250 million of outstanding common stock.
Ameren Corporation announced its third quarter 2026 financial results, reporting a GAAP diluted EPS of $2.42 compared to $2.35 for the same period in 2025. Driven by strong year-to-date performance and infrastructure investments, the company raised its 2026 earnings guidance range and established its 2027 outlook.
Third quarter 2026 GAAP diluted EPS was $2.42 versus $2.35 in the third quarter of 2025.
Raised 2026 earnings guidance range to $5.35 to $5.55 per diluted share.
Established 2027 earnings guidance range of $5.70 to $5.90 per diluted share.
Planned infrastructure investments of $38.1 billion to support projected rate base growth through 2031.
Mettler-Toledo International Inc. reported third quarter 2026 net sales of $1.094 billion, representing a 6% increase compared to the prior-year period. Diluted earnings per share rose to $12.29 from $10.57, while adjusted EPS grew 13% to $12.57, driven by improving market demand and solid execution. Management also raised its full-year 2026 adjusted EPS guidance range to $47.70 to $47.90.
Reported net sales for the third quarter of 2026 increased 6% to $1.094 billion.
Diluted earnings per share were $12.29, compared with $10.57 in the third quarter of 2025.
Adjusted diluted EPS increased 13% to $12.57 from $11.15 in the prior-year period.
Full-year 2026 adjusted EPS is forecast to be between $47.70 and $47.90.
Monster Beverage Corporation reported third quarter net sales of $2.56 billion, representing a 16.7 percent increase compared to the same period in 2025. Net income for the quarter rose 8.4 percent to $568.4 million, or $0.29 per diluted share.
Net sales increased 16.7 percent to $2.56 billion for the third quarter ended September 30, 2026.
Net income grew 8.4 percent to $568.4 million, with diluted earnings per share at $0.29.
International net sales increased 28.1 percent to $1.20 billion, representing 47 percent of total net sales.
The company repurchased approximately 2.3 million shares for $100.0 million during the third quarter.
Red Violet, Inc. reported third quarter 2026 results with revenue up 20% to $27.8 million and net income up 29% to $5.4 million, or $0.35 per diluted share. The company also said operating cash flow reached a record $12.7 million and that it had no debt as of September 30, 2026. The filing contains no guidance changes, and the headline figures all improved year over year.
Revenue rose 20% to $27.8 million; gross margin rose to 76% from 73%.
Net income rose 29% to $5.4 million; diluted EPS was $0.35 versus $0.29 a year earlier.
Closed a public offering with net proceeds of $108.7 million; cash and Treasury holdings totaled $165.7 million with no debt.
Liberty Media reported third-quarter 2026 results with higher revenue, operating income and Adjusted OIBDA than in the same quarter of 2025, helped by one more Formula 1 race. Nine-month revenue was flat at $2.9 billion, and MotoGP results fell because it held two fewer races. The company also said its exchange of Dr. John Malone's high-vote Series B shares closed on November 4, reducing his voting power to about 3%.
Q3 2026 revenue was $1.2 billion, up from $1,085 million; operating income was $237 million, up from $158 million.
Q3 Adjusted OIBDA was $353 million versus $297 million; net earnings attributable to Liberty stockholders were $163 million versus $13 million.
Nine-month revenue was $2.9 billion, flat year over year, and nine-month operating income was $389 million versus $371 million.
The Malone share exchange closed November 4, 2026; his aggregate voting power fell to approximately 3%.
Amphastar reported third-quarter 2026 net revenues of $207.6 million, up 8% from $191.8 million a year earlier. GAAP net income was $37.8 million, or $0.87 per diluted share, compared with $17.4 million, or $0.37, in the prior-year quarter, which included a $23.1 million litigation provision. Gross margin fell to 48.0% from 51.4%, and the board authorized a $50 million increase to the share buyback program.
Net revenues $207.6 million vs $191.8 million in Q3 2025, up 8%
GAAP diluted EPS $0.87 vs $0.37; adjusted non-GAAP diluted EPS $1.14 vs $0.93
Gross margin 48.0% vs 51.4%, mainly from lower average selling prices and higher remediation-related manufacturing costs
Board authorized a $50 million increase to the share buyback program on November 4, 2026
PDF Solutions reported third-quarter 2026 revenue of $68.3 million, up 20% from a year earlier and up 11% from the second quarter, with GAAP diluted EPS of $0.16 versus $0.03 a year earlier. The company reaffirmed its 20% annual revenue growth target for 2026, but ending backlog fell to $247.2 million from $270.7 million in the second quarter and $292.0 million a year earlier.
Total revenue $68.3 million in Q3 2026, up 20% from $57.1 million in Q3 2025
GAAP diluted EPS $0.16 vs. $0.03 in Q3 2025; non-GAAP diluted EPS $0.40 vs. $0.25
Ending backlog $247.2 million, down from $270.7 million in Q2 2026 and $292.0 million in Q3 2025
Company reaffirmed its 20% annual revenue growth target for 2026
Clarus reported third-quarter 2026 sales of $71.2 million, up 2.7% from $69.3 million a year earlier, and net income of $3.3 million ($0.09 per diluted share) versus a net loss of $1.6 million. The company raised its fiscal 2026 sales outlook to $251 million to $255 million and its adjusted EBITDA outlook to about $15 million to $17 million, while cash fell to $20.8 million and the strategic review of alternatives, including a possible sale of the business, continues with no set timetable.
Q3 2026 net income was $3.3 million, or $0.09 per diluted share, compared with a net loss of $1.6 million, or $(0.04), in Q3 2025.
Q3 2026 adjusted EBITDA was $6.8 million (9.6% margin), compared with $1.8 million (2.6% margin) a year earlier; the filing notes a benefit of about $0.6 million from IEEPA tariff refunds.
Full-year 2026 sales outlook is $251 million to $255 million, up from the prior $245 million to $255 million; free cash flow is now expected to be break even, versus a prior outlook of $6 million.
Cash and cash equivalents were $20.8 million at September 30, 2026, down from $36.7 million at December 31, 2025; the company reports no debt.
Reinsurance Group of America reported third-quarter net income available to shareholders of $456 million, or $6.92 per diluted share, up from $253 million, or $3.81 per diluted share, in the prior-year period. Adjusted operating income was $558 million, or $8.49 per diluted share, compared to $310 million, or $4.66 per diluted share, a year earlier. The board declared a regular quarterly dividend of $0.98 per share payable on December 1, 2026.
Net income available to shareholders rose to $456 million, or $6.92 per diluted share, for the third quarter ended September 30, 2026.
Adjusted operating income reached $558 million, or $8.49 per diluted share, compared to $310 million, or $4.66 per diluted share, in the prior-year quarter.
Consolidated net premiums totaled $5.4 billion for the quarter, marking a 25.0% increase over the prior-year period.
The board of directors declared a regular quarterly dividend of $0.98 per share, payable on December 1, 2026, to shareholders of record as of November 17, 2026.
Abacus reported third-quarter 2026 revenue of $76.9 million, up 22% from $63.0 million a year earlier, and GAAP net income of $14.5 million, up from $7.1 million. The company raised its full-year 2026 adjusted net income guidance to $104.5 million to $106.5 million and approved a 10% increase in its annual dividend to $0.22 per share, which reflects higher earnings and more cash returned to shareholders.
Q3 2026 total revenue $76.9 million vs. $63.0 million; diluted adjusted EPS $0.29 vs. $0.24
Adjusted EBITDA rose to $42.3 million from $37.9 million, but its margin fell to 55.0% from 60.2%
FY2026 adjusted net income guidance raised to $104.5 million to $106.5 million; Q4 adjusted EPS guided to $0.28 to $0.30
Annual cash dividend of $0.22 per share, up from $0.20; record date December 1, 2026, payable December 16, 2026
StandardAero reported third-quarter 2026 revenue of $1.56 billion and net income of $92.8 million, representing year-over-year growth across all major end markets. Driven by engine services growth, the company raised its full-year 2026 financial guidance and announced a $350 million accelerated share repurchase under an expanded $1.0 billion buyback authorization.
Third-quarter 2026 revenue increased 4.0% year-over-year to $1,557.4 million.
Net income for the quarter rose 36.2% to $92.8 million, with diluted GAAP EPS at $0.28.
Full-year 2026 guidance was updated to project revenue of $6,525 to $6,645 million and Adjusted EBITDA of $905 to $920 million.
The Board approved a $560.0 million increase to the share repurchase program, reaching a total authorization of $1.0 billion, alongside a planned $350.0 million accelerated share repurchase agreement.
Braemar Hotels & Resorts released a third-quarter 2026 earnings investor presentation on November 5, 2026. Comparable RevPAR rose 14.4% to $284 and comparable Hotel EBITDA rose 20.7% to $12.9 million, and the company reaffirmed its one-time full-year 2027 guidance.
Q3 2026 comparable total hotel revenue was $95.2 million, up 9.9% from a year earlier
Comparable Hotel EBITDA margin rose 122 basis points to 13.6%
Four Seasons Scottsdale was sold on October 28, 2026 for $372.0 million
The Ritz-Carlton, Lake Tahoe refinancing closed October 30, cutting the spread by 60 basis points and extending maturity to 2031
Valhi reported third quarter 2026 net income attributable to its stockholders of $30.2 million, or $1.06 per share, compared with a net loss of $22.2 million, or $.78 per share, a year earlier. The gain was driven mainly by higher operating income from its Chemicals Segment, and the company also declared a regular quarterly dividend of $0.08 per share.
Q3 2026 net sales were $589.0 million, up from $503.5 million in Q3 2025, with Chemicals sales up $84.2 million, or 18%.
Chemicals operating income was $60.5 million in Q3 2026, compared with a loss of $15.9 million a year earlier.
A non-cash deferred income tax benefit of $12.1 million ($.28 per share) related to proposed currency regulations boosted Q3 2026 net income.
Dividend of $0.08 per share is payable December 17, 2026, to stockholders of record on November 19, 2026.
Playboy reported third-quarter 2026 revenue of $31.7 million, up 9.4%, and net income of $1.9 million, up from $0.5 million a year earlier, with growth led by Honey Birdette and China licensing. Operating income rose to $4.0 million, helped by lower legal expenses and the release of a U.S. sales tax reserve, but the company still reported a net loss of $1.9 million for the nine months ended September 30, 2026. The company also agreed to acquire a Miami Beach property for a members club, with approximately $5.0 million of balance sheet cash committed.
Revenue was $31.7 million, up 9.4% from $29.0 million; Honey Birdette revenue rose 12.1% to $18.4 million.
Net income was $1.9 million, or $0.02 per share, compared with $0.5 million in the third quarter of 2025.
Adjusted EBITDA rose 95% to $7.9 million, the seventh consecutive quarter of positive adjusted EBITDA.
Nine-month net loss was $1.9 million; the company agreed to acquire a Miami Beach property and has committed about $5.0 million of cash.
Protagonist Therapeutics reported third quarter 2026 financial results, highlighted by net income of $220.0 million and license and collaboration revenue of $274.4 million, driven by partner payments following FDA approval of MIMRYLO. Cash, cash equivalents, and marketable securities reached $834.6 million as of September 30, 2026. The company also announced a $300 million share repurchase program authorized in September 2026.
Net income for the third quarter of 2026 was $220.0 million, or $3.07 per diluted share, compared to a net loss of $39.3 million, or $0.62 per diluted share, for the third quarter of 2025.
License and collaboration revenue reached $274.4 million for the third quarter of 2026, primarily driven by $266.6 million in proportional recognition from Takeda following the FDA approval of MIMRYLO.
Cash, cash equivalents, and marketable securities totaled $834.6 million as of September 30, 2026.
The Board of Directors authorized a $300 million share repurchase program announced on September 8, 2026.
EOG Resources released its third quarter 2026 operational and financial results, reporting a net income of $2.78 billion and diluted net income per share of $5.33. Total operating revenues reached $8.55 billion for the quarter ended September 30, 2026.
Reported third quarter 2026 net income of $2.78 billion, or $5.33 per diluted share.
Total operating revenues were $8.55 billion for the third quarter of 2026.
Net cash provided by operating activities totaled $3.81 billion for the quarter ended September 30, 2026.
TSS reported third-quarter 2026 revenue of $50.1 million, up 20% from a year earlier, with net income of $1.1 million compared with a net loss of $1.5 million in the prior-year quarter. The company raised its 2026 Adjusted EBITDA outlook to a range of $21 million to $23 million, but nine-month revenue of $140.5 million was down 24% from the prior-year period.
Q3 revenue $50.1 million, up 20%; Systems Integration revenue a record $16.1 million, up 75%
Q3 net income $1.1 million, diluted EPS $0.04, versus a net loss of $1.5 million and diluted EPS of ($0.06) a year earlier
2026 Adjusted EBITDA outlook raised to $21 million to $23 million
Nine-month revenue $140.5 million, down 24%, reflecting lower Procurement revenue
Kronos Worldwide reported third quarter 2026 net income of $34.8 million, or $.30 per share, compared with a net loss of $37.0 million, or $.32 per share, a year earlier. Net sales rose 18% to $541.1 million, driven by higher sales volumes and higher average TiO 2 selling prices, and segment profit reached $61.0 million. The company said end use demand remains below historical levels and expects softer fourth quarter demand and lower production volumes.
Q3 2026 net income $34.8 million ($.30 per share) vs. net loss of $37.0 million ($.32 per share) in Q3 2025
Q3 2026 net sales $541.1 million, up $84.2 million or 18%; TiO 2 sales volume rose 14%
Q3 2026 TiO 2 segment profit $61.0 million vs. a loss of $15.3 million in Q3 2025
Q3 2026 net income includes a $12.1 million non-cash deferred income tax benefit tied to proposed §987 currency regulations
Microchip Technology reported net sales of $1.622 billion for the second quarter of fiscal year 2027, representing a 42.2% increase from the same period last year. GAAP net income attributable to common stockholders reached $373.6 million, or $0.68 per diluted share, while non-GAAP net income was $559.2 million, or $0.97 per diluted share.
Net sales for the September 30, 2026 quarter were $1.622 billion, up 42.2% year-over-year and 9.2% sequentially.
GAAP EPS was $0.68 and Non-GAAP EPS was $0.97 per diluted share for the quarter.
The company returned approximately $247.6 million to common stockholders through dividends during the September quarter.
December quarter net sales are projected to be down 3% to up 1% sequentially, with a midpoint of down 1%.
NLI Holdings reported third quarter 2026 net income attributable to stockholders of $12.7 million, or $.26 per share, compared with a net loss of $7.8 million, or $.16 per share, a year earlier. For the first nine months of 2026, net income was $26.0 million, or $.53 per share, versus a net loss of $6.8 million, or $.14 per share, in the same period of 2025, driven by higher CompX and Kronos results. The filing furnishes a press release and contains no guidance.
Q3 2026 net sales of $44.0 million, up from $40.0 million; CompX segment profit rose to $6.4 million from $4.8 million
Kronos net sales of $541.1 million in Q3 2026, up $84.2 million, or 18%, from Q3 2025
Kronos income from operations was $57.9 million in Q3 2026, versus a loss of $19.2 million a year earlier
Q3 2026 net income included a $3.7 million ($.06 per share) non-cash deferred tax benefit at Kronos
Karman Space & Defense reported third-quarter 2026 revenue of $201.6 million, up 65.6% from a year earlier, and net income of $20.9 million, or $0.16 per diluted share, versus $0.06 a year earlier. The company raised its fiscal 2026 revenue outlook to $755 million to $760 million and its adjusted EBITDA outlook to $225 million to $227 million, which gives shareholders a higher expected full-year range.
Q3 revenue $201.6 million, up 65.6%; organic growth of 25% per the company
Net income $20.9 million ($0.16 per diluted share) vs. $7.6 million ($0.06) a year earlier
Adjusted EBITDA $60.5 million, up from $37.7 million; adjusted EPS $0.19 vs. $0.10
Fiscal 2026 guidance raised to $755M-$760M revenue and $225M-$227M adjusted EBITDA; backlog $1.7 billion at September 30, 2026
Live Nation Entertainment reported third quarter 2026 financial results, posting revenue of $10.1 billion and operating income of $892 million, driven by strong global concert attendance and ticket sales. For shareholders, the results demonstrate continued double-digit top-line growth and strong cash generation supporting ongoing venue investments.
Quarterly revenue reached $10.1 billion, representing a 19% increase compared to the third quarter of 2025.
Operating income for the quarter was $892 million, up 13% year-over-year.
Adjusted operating income (AOI) grew 14% to $1.18 billion for the third quarter.
Global fan attendance rose 19% to 61 million for the quarter, led by strong international market growth.
Funko reported third-quarter 2026 results, with net sales up 3.0% to $258.3 million and net income of $7.5 million, or $0.13 per diluted share, compared with $0.9 million, or $0.02, a year earlier. The company reiterated its full-year 2026 guidance for net sales, gross margin and adjusted EBITDA, so shareholders have no change to the outlook.
Q3 net sales rose 3.0% to $258.3 million; Core Collectibles rose 4.8%, while Loungefly fell 9.8%
Adjusted EBITDA was $32.1 million, up from $24.4 million; gross margin was 45.2%, up from 40.2%
Full-year 2026 guidance reiterated: net sales flat to up 3%, gross margin 46% to 47%, adjusted EBITDA $100 million to $110 million, including a $25.4 million second-quarter tariff-related benefit
Moelis & Company reported third-quarter 2026 results with revenue up year over year, and its board declared a $0.65 per share quarterly dividend. The company said the revenue increase reflects higher average fees earned per completed transaction, and it reported record first nine months revenue of $1,154.7 million.
Q3 2026 GAAP revenue was $425.6 million, up from $356.9 million; adjusted revenue was $425.6 million, up 13% from $376.0 million
Q3 2026 GAAP diluted EPS was $0.74 versus $0.67; adjusted diluted EPS was $0.75 versus $0.68
Nine-month 2026 GAAP diluted EPS was $1.83 versus $1.84 in the prior year period; adjusted EPS was $1.87 versus $1.86
Quarterly dividend of $0.65 per share is payable December 17, 2026 to holders of record on November 16, 2026; cash and short-term investments were $658.7 million with no debt
DXP Enterprises reported third quarter 2026 results for the period ended September 30, 2026, with sales of $587.2 million, up 14.3% from a year earlier, and net income of $26.9 million, up 24.2%. Diluted earnings per share were $1.64 compared with $1.31 in the third quarter of 2025, and the company completed five acquisitions through the quarter.
Sales were $587.2 million versus $513.7 million in the third quarter of 2025; acquisitions contributed $48.8 million.
Net income was $26.9 million versus $21.6 million; diluted EPS was $1.64 versus $1.31.
Adjusted EBITDA was $67.3 million, up 19.0%, with an Adjusted EBITDA margin of 11.5% versus 11.0%.
Free cash flow was $14.4 million versus $28.1 million a year earlier; total debt was $839.5 million as of September 30, 2026.
Devon Energy reported third-quarter 2026 net earnings of $1.0 billion, or $0.88 per diluted share, along with $2.0 billion in adjusted free cash flow. The company raised its year-end 2026 synergy run-rate expectations to approximately $350 million and maintained its full-year guidance while providing an initial 2027 outlook.
Generated $2.8 billion of operating cash flow and $2.0 billion of adjusted free cash flow in the third quarter of 2026.
Agreed to sell Eagle Ford assets for $4.2 billion in cash on October 8, 2026, with closing expected in early 2027.
Returned $1,530 million to shareholders during the quarter through dividends, share repurchases, and debt reduction.
Raised expected year-end 2026 synergy run rate to approximately $350 million.
Clean Energy Fuels reported third-quarter 2026 revenue of $112.2 million, up from $106.1 million a year earlier, and a net loss of $5.7 million, down from $23.8 million. Adjusted EBITDA rose to $27.2 million from $17.3 million, and the company raised its 2026 Adjusted EBITDA outlook to $75 million to $80 million from $70 million to $75 million. It still expects a 2026 GAAP net loss of $50 million to $55 million.
Q3 2026 revenue of $112.2 million, up from $106.1 million in Q3 2025; RNG gallons sold rose 9.0% to 66.8 million.
Net loss attributable to Clean Energy narrowed to $5.7 million, or $0.03 per share, from $23.8 million, or $0.11 per share.
2026 Adjusted EBITDA outlook raised to $75 million to $80 million; expected 2026 GAAP net loss remains $50 million to $55 million.
Sold $30.7 million of federal tax credits from seven RNG facilities; Sean Wine named Chief Revenue Officer and JJ Armstrong Chief Financial Officer.
FTAI Infrastructure reported third quarter 2026 revenue of $219.0 million, up from $140.6 million a year earlier, and a smaller loss per share of $1.27 compared with $1.38. The company also declared a $0.03 per share dividend, reported a record Adjusted EBITDA of $95.3 million, and said it expects to close the Long Ridge sale by the end of November and a $255 million acquisition from USD Group LLC in November. The company still posted a net loss, with interest expense of $116.5 million and asset impairment of $28.6 million in the quarter.
Total revenues were $219.0 million for the quarter ended September 30, 2026, compared with $140.6 million a year earlier.
Net loss attributable to common stockholders was $150.2 million, or $1.27 per share, versus $159.2 million, or $1.38 per share, in the prior-year quarter.
Adjusted EBITDA was $95.3 million, a quarterly record according to the company, compared with $70.9 million a year earlier.
The Board declared a $0.03 per share dividend payable December 7, 2026 to holders of record on November 23, 2026.
Profound Medical reported third-quarter 2026 revenue of approximately $9.8 million, up 86% year-over-year, and a net loss of about $7.7 million, or $0.21 per share, narrower than the prior-year quarter. The company projects full-year 2026 revenue of at least $25.0 million and announced that Richard Fabian will succeed Arun Menawat as CEO effective January 14, 2027.
Q3 2026 revenue of approximately $9.8 million, up 86% year-over-year; gross margin of 78% versus 74% a year earlier
Net loss improved 3% to approximately $7.7 million ($0.21 per share) from $8.0 million ($0.26 per share)
Full-year 2026 revenue projected at least $25.0 million; gross margin expected at 70% or higher
Richard Fabian becomes CEO effective January 14, 2027; Arun Menawat becomes Executive Chairman
Skyward Specialty Insurance Group reported third quarter 2026 results for the period ended September 30, 2026. Net income rose to $49.8 million from $45.9 million a year earlier, while GAAP diluted earnings per share slipped to $1.09 from $1.10, and diluted operating earnings per share increased to $1.28 from $1.05.
Managed premiums rose 12.5% to $1.32 billion; gross written premiums rose 9.0% to $803.5 million.
Net income was $49.8 million, up from $45.9 million; diluted EPS was $1.09 versus $1.10 a year earlier.
Diluted operating EPS was $1.28 versus $1.05; the combined ratio was 89.9%, and the ex-cat combined ratio was 88.1%.
Book value per share was $28.74, up 15.3% from December 31, 2025. The company will hold a conference call on November 6, 2026 at 10:00 a.m. Eastern.
James Hardie reported results for the quarter ended September 30, 2026, with continuing-operations net sales of $1.428 billion, up 24% from a year earlier. Net income from continuing operations was $149.8 million, compared with a loss of $64.3 million a year earlier. The company reaffirmed its fiscal 2027 net sales and Adjusted EBITDA guidance and raised its free cash flow target to more than $650 million. For shareholders, sales and profit improved, but management expects Adjusted EBITDA to be lower in the third quarter and second half.
Net sales from continuing operations were $1.428 billion, up 24%; Deck, Rail & Accessories sales rose 51% to $387.0 million
Diluted earnings per share from continuing operations were $0.26, versus a loss of $0.11 a year earlier; Adjusted EBITDA was $454.7 million, a 31.8% margin
Fiscal 2027 net sales and Adjusted EBITDA guidance were reaffirmed; free cash flow target raised to more than $650 million
Third-quarter Total Adjusted EBITDA guidance is $298 million to $320 million, which the company expects to be lower
Eton Pharmaceuticals reported third quarter 2026 revenue of $57.9 million, up from $22.5 million a year earlier, and raised its 2026 revenue guidance to more than $175 million from more than $145 million. GAAP net income of $35.2 million, or $1.06 per diluted share, was boosted by a $12.9 million income tax benefit from releasing a valuation allowance, while non-GAAP diluted EPS was $0.50.
Q3 2026 revenue was $57.9 million versus $22.5 million in Q3 2025, driven mainly by the addition of HEMANGEOL sales.
Adjusted EBITDA was $28.5 million, or 49% of revenue, compared with $2.9 million, or 13%, a year earlier.
2026 revenue guidance was raised to more than $175 million from more than $145 million; Adjusted EBITDA margin guidance was raised to at least 40% from at least 35%.
Cash and cash equivalents were $55.6 million as of September 30, 2026.
Adicet Bio reported a third-quarter 2026 net loss of $18.9 million, or $1.76 per share, compared with a net loss of $26.9 million, or $4.72 per share, in the same period of 2025. The company said its cash, cash equivalents and short-term investments of $100.9 million as of September 30, 2026, are expected to fund operating expenses into the second half of 2027.
Net loss of $18.9 million, or $1.76 per share, for the quarter ended September 30, 2026, versus $26.9 million, or $4.72 per share, a year earlier
R&D expenses fell to $15.6 million from $22.9 million, and G&A expenses fell to $4.2 million from $5.1 million
Cash, cash equivalents and short-term investments were $100.9 million on September 30, 2026, down from $158.5 million on December 31, 2025
Company expects current cash to fund operating expenses into the second half of 2027
A10 Networks reported third-quarter 2026 revenue of $91.5 million, up 22.6% from a year earlier, with GAAP net income of $17.2 million, or $0.23 per diluted share. The company raised its full-year 2026 revenue growth outlook to about 16%, from 12-14%, and its non-GAAP diluted EPS outlook to $1.08-$1.10, and the Board approved a $0.06 quarterly dividend.
Q3 2026 revenue of $91.5 million, up 22.6% year over year; non-GAAP diluted EPS of $0.31 versus $0.23 a year earlier
Full-year 2026 revenue growth outlook raised to about 16%, from prior guidance of 12-14%
Full-year 2026 non-GAAP diluted EPS expected at $1.08-$1.10, growth of 20-22% over 2025, versus prior guidance of 14-16% growth
Quarterly dividend of $0.06 per share payable December 1, 2026, to holders of record on November 16, 2026
Mach Natural Resources reported third-quarter 2026 net income of $10 million and Adjusted EBITDA of $183 million, compared with a net loss of $35.7 million and Adjusted EBITDA of $124 million in the same quarter of 2025. The company declared a $0.22 per common unit distribution and gave full-year 2027 guidance of $275 million to $325 million in development capital and 134 to 142 MBoe/d in production, which shareholders will weigh against the lower 2026 rig count it reported.
Q3 2026 net income was $10 million, versus a net loss of $35.7 million in Q3 2025 per the filing's reconciliation table
Q3 2026 Adjusted EBITDA was $183 million, versus $124 million a year earlier
Quarterly distribution of $0.22 per common unit, payable November 30, 2026, to unitholders of record as of November 16, 2026
2027 guidance: $275 million to $325 million in total development capital and 134 to 142 MBoe/d in production; operated rigs reduced from three to one after quarter-end
Elicio Therapeutics reported third quarter 2026 results on November 5, 2026, with a net loss of $8.0 million, down from $10.1 million a year earlier. The company said its cash and cash equivalents of $30.9 million as of September 30, 2026 will support operations into the second quarter of 2027, and it discussed Phase 2 AMPLIFY-7P results that did not meet the primary disease-free survival endpoint in the intent-to-treat population.
Net loss was $8.0 million, or $0.30 per share, versus $10.1 million, or $0.60 per share, in the third quarter of 2025.
R&D expense was $4.9 million versus $5.0 million; G&A expense rose to $3.6 million from $3.0 million.
Cash and cash equivalents were $30.9 million at September 30, 2026, with an expected runway into the second quarter of 2027.
AMPLIFY-7P missed its primary DFS endpoint in the intent-to-treat population; pre-specified subgroup analyses showed risk reductions of 49% and 43% in ctDNA-negative and ctDNA-positive patients.
SiriusPoint reported third-quarter 2026 net income available to common shareholders of $87 million, or $0.74 per diluted share, and operating earnings per share of $0.88, up 19%. The company also agreed to a loss portfolio transfer with RiverStone covering substantially all remaining run-off reserves, which it expects to unlock over $200 million of capital, subject to regulatory approval. Core combined ratio worsened to 90.1% from 89.1% a year earlier.
Q3 net income available to common shareholders of $87 million, or $0.74 per diluted share, versus $86.8 million a year earlier
Operating EPS of $0.88 versus $0.74 in Q3 2025; nine-month diluted EPS of $2.14 versus $1.71
Core gross written premium up 13.7% to $990.6 million; core combined ratio 90.1% versus 89.1%
RiverStone loss portfolio transfer is subject to regulatory approval and expected to unlock over $200 million of capital; webcast set for November 6, 2026 at 8:30 a.m. ET
HASI reported third-quarter 2026 results on November 5, 2026, with GAAP diluted EPS of $1.04 versus $0.61 a year earlier and Adjusted EPS of $0.82 versus $0.80. The company reaffirmed its 2026 Adjusted EPS guidance of $3.55 to $3.65 and declared a quarterly dividend of $0.425 per share. Nine-month GAAP diluted EPS was $1.47, down from $1.79, and the quarter included a $21 million economic loss on a consolidated project company.
GAAP diluted EPS was $1.04 in Q3 2026, compared with $0.61 in Q3 2025; GAAP net income to controlling stockholders was $146 million versus $83 million.
Adjusted EPS was $0.82 in Q3 2026, compared with $0.80 in Q3 2025; Adjusted Recurring Net Investment Income was $121 million, up 15%.
Company reaffirmed 2026 Adjusted EPS guidance of $3.55 to $3.65 and expects minimal ATM share issuances for the full year 2026.
Board approved a quarterly cash dividend of $0.425 per share, payable January 8, 2027, to holders of record as of December 29, 2026.
Genpact Limited announced its third quarter 2026 financial results, reporting net revenues of $1.385 billion, representing a 7.3% increase year-over-year. Driven by strong performance in Advanced Technology Solutions and margin expansion, the company raised its full-year 2026 guidance for gross margin and adjusted diluted earnings per share.
Net revenues for Q3 2026 were $1.385 billion, up 7.3% year-over-year.
Advanced Technology Solutions net revenues grew 30.3% year-over-year to $405 million.
Diluted earnings per share for the quarter was $0.89, compared to $0.83 in Q3 2025.
Genpact repurchased approximately 870,000 common shares for about $31 million during the quarter.
Workiva reported third quarter 2026 total revenue of $263 million, up 17% from a year earlier, and GAAP net income of $19 million, or $0.35 per diluted share, compared with $3 million, or $0.05, in the third quarter of 2025. The company also issued fourth quarter and full-year 2026 guidance, with full-year total revenue expected at $1.041 billion to $1.044 billion.
Total revenue was $263 million, up 17% from $224 million; subscription and support revenue was $246 million, up 17%.
GAAP net income was $19 million, or $0.35 per diluted share, versus $3 million, or $0.05, a year earlier.
Non-GAAP operating margin was 18.3%, up from 12.7%; the non-GAAP tax provision now uses a fixed 22% rate, applied to prior periods as well.
Fourth quarter 2026 total revenue is expected at $275 million to $278 million; full-year 2026 free cash flow margin is expected to be about 21%.
Alarm.com reported third-quarter 2026 total revenue of $279.4 million, up 9.0% from a year earlier, and GAAP diluted EPS of $0.66 versus $0.65. GAAP net income slipped to $34.3 million from $35.1 million. The company raised its full-year 2026 guidance for SaaS and license revenue and non-GAAP adjusted EBITDA, which matters to shareholders because it sets a higher expected range for the year.
Total revenue rose 9.0% to $279.4 million; SaaS and license revenue rose 9.0% to $191.2 million.
GAAP diluted EPS was $0.66 versus $0.65; GAAP net income was $34.3 million versus $35.1 million.
Full-year 2026 SaaS and license revenue guidance is $756.1 million to $756.3 million, up $12.2 million from the midpoint given in February 2026.
Full-year 2026 non-GAAP adjusted EBITDA guidance was raised to $227.0 million to $229.0 million.
Astrana Health reported third-quarter 2026 results on November 5, 2026, with revenue of $1,023.6 million, up 7%, and net income attributable to Astrana of $13.0 million, up from $0.4 million a year earlier. The company also narrowed its full-year 2026 guidance for revenue, adjusted EBITDA and free cash flow and gave fourth-quarter guidance; the filing does not state prior guidance, so the direction of the change is not shown. For shareholders, headline profit and revenue both improved, while adjusted EPS rose 4% to $0.71.
Q3 2026 total revenue $1,023.6 million, up 7%; adjusted EBITDA $77.2 million, up 13%
Net income attributable to Astrana $13.0 million vs $0.4 million; diluted EPS $0.26 vs $0.01
Adjusted EPS - diluted $0.71, up 4% from $0.68
Full-year 2026 guidance: total revenue $3.9 billion to $4.0 billion; adjusted EBITDA $261 million to $274 million; free cash flow $107.5 million to $130 million
AEye reported third quarter 2026 revenue of $506 thousand, about 10 times the $50 thousand in Q3 2025, and gave its first revenue guidance, expecting fourth quarter revenue to roughly double to about $1 million. The GAAP net loss widened to $11.2 million from $9.3 million, but the loss per share narrowed to $0.24 from $0.30, and the company expects 2026 cash consumption of $35 million.
Q3 2026 revenue was $506 thousand, up from $50 thousand in Q3 2025 and about 2.5 times Q2 2026
GAAP net loss was $11.2 million, or $0.24 per share, versus $9.3 million, or $0.30 per share, a year earlier
Gross margin improved to (35)% from (80)% in Q2 2026
Q4 2026 revenue is expected to approximately double Q3 revenue to about $1 million; full-year 2026 cash consumption is expected to be $35 million
Applied Optoelectronics reported third-quarter 2026 revenue of $269.9 million, more than double the $118.6 million a year earlier, and GAAP net income of $6.3 million, compared with a net loss of $17.9 million in the third quarter of 2025. The company also expects fourth-quarter 2026 revenue of $385 million to $420 million, but its CFO said the 2027 US capacity expansion will take longer than expected due to power and construction issues.
Q3 2026 revenue was $269.9 million, up from $118.6 million in Q3 2025 and $191.9 million in Q2 2026.
GAAP net income was $6.3 million, or $0.07 per basic share, versus a net loss of $17.9 million in Q3 2025.
Non-GAAP gross margin was 28.7%, down from 31.0% in Q3 2025.
Q4 2026 outlook: revenue of $385 million to $420 million; non-GAAP net income of $45.9 million to $60.4 million.
ICU Medical reported third quarter 2026 GAAP revenue of $560.4 million, up from $537.0 million a year earlier, and GAAP net income of $26.8 million, or $1.07 per diluted share, compared with a net loss of $3.4 million in the prior-year quarter. The company reaffirmed its full-year 2026 guidance and now expects to finish toward the higher end of the range, which matters to shareholders because it signals the company expects its annual results to land near the top of its prior outlook.
Q3 2026 GAAP revenue $560.4 million vs. $537.0 million in Q3 2025; GAAP gross margin 42% vs. 37%
Q3 2026 adjusted diluted EPS $2.44 vs. $2.03 in Q3 2025; adjusted EBITDA $113.9 million vs. $105.9 million
Full-year 2026 guidance reaffirmed: GAAP net income $73 million to $83 million, adjusted EBITDA $415 million to $435 million, adjusted diluted EPS $8.60 to $9.00
Company expects to end fiscal 2026 toward the higher end of the guidance range; results released November 5, 2026
CarGurus reported third-quarter 2026 results for the period ended September 30, 2026, with revenue up 12% year over year to $258.4 million and GAAP net income from continuing operations up 2% to $52.8 million. The company also issued fourth-quarter and full-year 2026 guidance and authorized a $250.0 million share repurchase program, which matters to shareholders because it signals both growth in the core business and capital returned to stockholders.
Q3 2026 revenue of $258.4 million, up 12% year over year and at the high end of guidance; Adjusted EBITDA from continuing operations of $89.7 million, up 9%
Q3 diluted EPS from continuing operations of $0.59, versus $0.52 a year earlier; nine-month GAAP net income from continuing operations fell 6% to $134.2 million
Fourth-quarter 2026 guidance: revenue of $258.5 million to $263.5 million and non-GAAP EPS of $0.73 to $0.79
Board authorized a $250.0 million share repurchase program; nine-month impairments totaled $20.2 million
Alector reported third quarter 2026 collaboration revenue of $162.9 million, up from $3.3 million a year earlier, after recognizing remaining deferred revenue following GSK's July 6, 2026 termination notice. The company swung to net income of $124.6 million, or $1.11 per share, from a net loss of $34.7 million, and said it has funded operations into the second half of 2029 with the Genentech upfront payment and October offering proceeds.
Collaboration revenue was $162.9 million, versus $3.3 million, driven by recognition of remaining deferred revenue after GSK's July 6, 2026 termination notice.
Net income was $124.6 million, or $1.11 per share, compared with a net loss of $34.7 million, or $0.34 per share, a year earlier.
Genentech licensed AL050 with a $100 million upfront payment and eligibility for up to $1.17 billion in milestones plus tiered royalties.
Cash, cash equivalents and investments were $138.7 million at September 30, 2026; the October offering raised about $75.0 million gross.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.